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CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit under 35 U.S.C. 
S119(e) of U.S. Provisional Application No. 61/377,871, 
filed Aug. 27, 2010, which is hereby incorporated by refer 
ence in the present disclosure in its entirety. 
BACKGROUND 
1. Field 
The present disclosure relates generally to piperazinylpy 
rimidine analogs and uses thereof. The invention also relates 
to methods of preparing these compounds. 
2. Related Art 
The human kinome, represented by 518 kinases, is a 
widely investigated protein family on biological, chemical, 
and clinical levels. Protein kinases are involved in the major 
ity of signal transduction pathways regulating the cell 
machinery of Survival, proliferation, and maintenance. 
Accordingly, several pathological abnormalities are corre 
lated with aberrations in the operational integrity and accu 
racy of certain kinases inside the cell, making kinases attrac 
tive targets for treating, diagnosing, and establishing 
personalized therapies of various disorders such as different 
malignancies, neurodegenerative disorders, rheumatoid 
arthritis, autoimmune diseases, and others (Eglen, R. M.; 
Reisine, T. Assay and Drug Development Technologies 2009, 
7, 22-43; Eglen, R. M.; Reisine, T. Expert Opinion on Drug 
Discovery 2010, 5, 277-290; Parikh, K. Peppelenbosch, M. 
P. Cancer Research 2010, 70, 2575-2578; McDermott, U.: 
Settleman, J. Journal of Clinical Oncology 2009, 27, 5650 
5659). 
Kinase inhibitors, either Small molecules or monoclonal 
antibodies, represent a class of molecularly targeted antican 
cer agents; approximately 14 kinase targeting agents have 
earned FDA approval during the last two decades as either 
anticancer or antiangiogenic agents. In comparison, not as 
many agents targeting other cancer-relevant families such as 
Bcl-2 proteins, histone deacetylases, and phosphatases, have 
gained regulatory approval. Furthermore, the discovery, pre 
clinical, and clinical development of novel kinase inhibitors 
currently are the focus of pharmaceutical industry research 
efforts, especially those seeking novel and effective cancer 
controlling agents (Selzer, E. Expert Review of Clinical Phar 
macology 2010, 3, 161-163). 
The design of selective kinase inhibitors has proven to be 
challenging due to the conservation of the ATP binding site, 
targeted by most inhibitors, among different kinases. Several 
design strategies, both computer assisted, bioinformatics 
aided, and structure based, have been implemented to tailor 
more selective kinase inhibitors against a Subset of kinases or 
certain kinase subfamilies (Eglen, R. M.; Reisine, T. Expert 
Opinion on Drug Discovery 2010, 5,277-290; Akritopoulou 
Zanze, I.: Hajduk, P. J. Drug Discovery Today 2009, 14, 
291-297; Bogoyevitch, M. A.; Fairlie, D. P. Drug Discovery 
Today 2007, 12, 622-633; Huang, D. et al. Bioinformatics 
2009, 26, 198-204; Kirkland, L.O.; McInnes, C. Biochemical 
Pharmacology 2009, 77, 1561-1571; Smyth, L.A.: Collins, I. 
Journal of Chemical Biology 2009, 2, 131-151; Aronov, A.M. 
et al. Journal of Medicinal Chemistry 2008, 51, 1214-1222; 
Knight, Z.A.; Shokat, K. M. Chemistry and Biology 2005, 12, 
621-637). One successful example is lapatinib, which is 













mutant EGFR subfamily members and is currently utilized 
clinically in combination with capecitabine for metastatic 
breast cancer. In contrast, Sunitinib, another Successfully mar 
keted kinase inhibitor, has been shown in several studies to be 
a highly promiscuous agent capable of interacting with more 
than 15% of kinases with a very high affinity (Kd-100 nM) 
(Morphy, R. Journal of Medicinal Chemistry 2010, 53, 1413 
1437; Karaman, M. W. et al. Nature Biotechnology 2008, 26, 
127-132). The selectivity of lapatinib compared to the pro 
miscuity of Sunitinib is usually rationalized by the observa 
tion that lapatinib is a type-II inhibitor which binds to the 
ATP-binding site as well as penetrating the adjacent allosteric 
binding site of its target kinases, whereas Sunitinib is a type-I 
inhibitor that binds mainly to the ATP-binding site of several 
kinases (Gajiwaia, K. S. Proceedings of the National Acad 
emy of Sciences of the United States of America 2009, 106, 
1542–1547; Wood, E. R. et al. Cancer Research 2004, 64, 
6652-6659). However, it is unjustified, according to several 
published reports, to claim that every type-I kinase inhibitoris 
promiscuous and that every type-II inhibitor is selective 
(Karaman, M. W. et al. Nature Biotechnology 2008, 26, 127 
132). Additionally, a given small molecule kinase inhibitor 
usually tends to recognize a given conformational ensemble 
of its target kinase(s) that may happen to differentially belong 
to either the active and/or the inactive state. That is to say that 
a type-I inhibitor, for example, may still bind to the inactive 
form of its kinase but with less affinity than with the active 
state. Considering another dimension of variability, some 
inhibitors interact potently with both the active and the inac 
tive forms of their targeted kinases. For example, MK-2461 is 
able to bind with considerable potency to both the phospho 
rylated and the unphosphorylated forms of c-MET kinase 
with a measured binding constant (Kd) of 4.4 and 27.2 nM 
respectively (Pan, B. S. et al. Cancer Research 2010, 70. 
1524-1533). Contrary to the behavior of MK-2461, Sunitinib 
exhibits a strong differential selectivity towards the unacti 
vated wild-type KIT versus the active form (Gajiwaia, K.S. et 
al. Proceedings of the National Academy of Sciences of the 
United States of America 2009, 106, 1542–1547). Generally 
speaking, the clinical fact that both lapatinib and Sunitinib 
have successfully helped save or at least improve the life 
quality of certain cancer patient populations illustrates that, 
when it comes to kinase inhibitors, it is arguable that selec 
tivity is always a virtue and non-selectivity is a constant 
drawback. In fact, Some kinase modulating agents may 
achieve better clinical outcomes via targeting several kinases 
whereas others can cause troublesome side effects even while 
being selective (Petrelli, A.; Giordano, S. Current Medicinal 
Chemistry 2008, 15, 422-432). Moreover, small molecules 
generally and kinase inhibitors specifically are usually pro 
miscuous hitters of several protein families and that could be 
why not all potent kinase inhibitors survive through the drug 
development process (McGovern, S. L.; Shoichet, B. K. Jour 
nal of Medicinal Chemistry 2003, 46, 1478-1483). 
The phenomenon of kinase inhibitors being mostly non 
selective has inspired the founding of several high-through 
put kinase profiling screens in order to determine intended as 
well as off-target kinases affected by a given kinase inhibitor 
(Karaman, M. W. et al. Nature Biotechnology 2008, 26, 127 
132; Fedorov, O. et al. Proceedings of the National Academy 
of Sciences of the United States of America 2007, 104,20523 
20528; Ma, H. et al. Expert Opinion on Drug Discovery 2008, 
3, 607-621). These screens have been used to investigate the 
kinase binding potential or the functional inhibitory activity 
of a given Small molecule against a large panel of kinases and 
thereby have facilitated uncovering some of the structural 
features relevant to promiscuity. However, it is now appreci 
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ated that a given kinase may be more promiscuous than 
another even with a difference of only a few amino acids 
because the conformational space of the kinase depends on 
structural features at the primary, secondary, and tertiary lev 
els (Bamborough, P. et al. Journal of Medicinal Chemistry 
2008, 51, 7898-7914). A deeper understanding of protein 
kinase promiscuity in cases where there are correlations 
between the ATP-binding sites of certain subfamilies that are 
not closely related based on sequence similarity is needed 
(Kinnings, S. L.; Jackson, R. M. Journal of Chemical Infor 
mation and Modeling 2009, 49,318-329). Resistance through 
several mechanisms, most frequently single point mutation, 
has been developed by cancer cells towards several kinase 
inhibitors; those who target proliferation and/orangiogenesis 
including both selective and non-selective kinase inhibitors 
(Christoffersen, T. et al. European Journal of Pharmacology 
2009, 625, 6-22; Martin, A. P. et al. Cancer Biology and 
Therapy 2010, 8, 2084-2096: Pages, G.; Grepin, R. Journal of 
Oncology 2010). 
Thus, there remains a need for novel protein kinase inhibi 
tor compounds with desirable pharmaceutical properties. 
SUMMARY 
The present invention provides piperazinylpyrimidine ana 
logs which may inhibit cell proliferation and/or induce cell 
apoptosis. The compounds comprise a piperazinylpyrimidine 
core group that is linked to a quinazoline or a quinazoline 
derivative. The quinazoline derivative may include a six 
membered pyrimidine ring fused to an optionally substituted 
aryl or heteroaryl ring with 5-6 ring atoms. 
The compounds of the invention exert biological activity in 
assays described herein. For example, compounds of the 
invention are cytotoxic in a cellular screening assay described 
herein. Though not limiting the invention by any theory, it is 
believed that the compounds localize in the hinge region of 
protein kinases and extend either through the ATP-binding 
groove or towards the adjacent allosteric site. The present 
invention also provides methods of preparing these com 
pounds, and methods of using the same. 
In one aspect, the present invention provides a compound 
of formula (I), (II), or (III): 
(I) 
2 3 R9 R4 R 
"Sk" - N N R10 \ X-N N-( \ 
N { o 
R5 R8 




R9 R. R. N 
R R 7 -N "k" iss--- R 14 
R10 N X-N N-Q 
N - K (R12) 
R11 R5 6 R )m pi 
R R 13 R 


















=N R 14 N 
R10 \ X-N N-Q /= 
N N s? So R16 V. A 
R11 R R R° R' R13 (R): 
N 
R15 YR 7 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 
bonded to one or more additional aryl, heterocyclic, or het 
eroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R', and R is independently 
selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R, R', R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR, S(O)R, 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted, with the proviso that R' for formula 
(I) must not be hydrogen; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. In some 
embodiments, Qis C=O. In other embodiments, each R', R, 
R. R. R. R. R. and R is hydrogen. In certain embodi 
ments, each RandR'' is independently selected from hydro 
gen, optionally Substituted alkyl, optionally Substituted aryl, 
halo, OR, NR, SR, CN, COOR, CONR, COR, CH(OH)R, 
and NO. In some embodiments, each R' is independently 
selected from optionally substituted alkyl, optionally substi 
tuted aryl, halo, OR, NR, SR, CN, COOR, CONR, COR, 
CH(OH)R, and NO. In some preferred embodiments, each 
R" is independently selected from optionally substituted 
alkyl or optionally substituted aryl. In other preferred 
embodiments, each R" is -(CH2). Ar, wherein p is 1-2 
and Ar is optionally substituted phenyl. In other preferred 
embodiments, each R and R'' is hydrogen and each R" is 
optionally substituted alkyl. In some embodiments, each R' 
is independently selected from methyl, ethyl, propyl, isopro 
pyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, 
and benzyl. In some preferred embodiments, each R" is 
independently selected from optionally substituted ethyl or 
benzyl. In some embodiments, each R' may be indepen 
dently selected from optionally substituted alkyl, optionally 
substituted aryl, halo, OR, NR, SR, CN, COOR, CONR, 
COR, CH(OH)R, and NO. In some preferred embodiments, 
each R' is hydrogen. In the above formulas (I), (II), and (III), 
W represents a ring that includes two ring atoms of one of the 
pyrimidine rings. W is typically an optionally substituted 5 
or 6-membered aromatic or heteroaromatic ring that is 
optionally fused to another substituted aryl, heteroaryl, het 
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erocyclic, or carbocyclic group. Frequently, W is an option 





VVVVV WMAP s 
A D 
V / 10 
B-C 
wherein each A, B, C, and D is independently NorCR' in 
any combination. In certain embodiments, W may include 15 
one of the following structures: 
N R 
-------- N ------- - 
mimw miw 2O 




www rviv s 
\ , / 30 
(R2) 
wherein each R'' is independently selected from the group 35 
consisting of hydrogen, optionally Substituted alkyl, option 
ally substituted aryl, halo, OR, NR, SR, CN, COOR, 
CONR, COR, CH(OH)R, and NO. In other embodiments, 
W may include one of the following structures: 
40 
N---, N--- 
N -------- N 
www rviv VVVVV VVivr and 




In some preferred embodiments, W is: 55 
N- R 
w R. 60 
65 
W may also represent an optionally substituted 5-membered 
ring having the following structure: 
wherein X and Y are N or CR': 
Z is selected from the group consisting of NR", O, and S; 
and 
R’ is hydrogen or R''. In other embodiments, W may 





- - - - N - - - - N 
R12 
wherein each R' is independently selected from the group 
consisting of hydrogen, optionally Substituted alkyl, and 
optionally substituted aryl. In certain embodiments, W may 
include one of the following structures: 
W may also represent an optionally substituted 5-membered 
ring having the following structure: 
wherein X is selected from the group consisting of NR', 
O, and S; 
Y and Z are N or CR'; and 
R’ is hydrogen or R''. In certain embodiments, W is 
selected from the group consisting of: 
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wherein each R'' is independently selected from the group 
consisting of hydrogen, optionally Substituted alkyl, and 
optionally substituted aryl. In certain embodiments, W may 
include one of the following structures: 
N--- N--- 
A R. F st - - - - S - - - --. N 
- N and 
w F 
HN 2 OS 2 
N 
N- - - 
wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted aryl; 
and wherein each R" is independently selected from the 
group consisting of hydrogen, optionally Substituted alkyl, 
optionally substituted aryl, halo, OR, NR, SR, CN, COOR, 
CONR, COR, CH(OH)R, and NO. In some preferred 
embodiments, the compound is: 
8 
In some preferred embodiments, the compound is: 
O N / \ O / R. 
5 R -(- N y 
NH = S(R2) 
10 wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted aryl; 
and wherein each R" is independently selected from the 
group consisting of hydrogen, optionally Substituted alkyl, 
optionally substituted aryl, halo, OR, NR, SR, CN, COOR, 
CONR, COR, CH(OH)R, and NO. In some preferred 
embodiments, the compound is: 
=N O N 




In some preferred embodiments, the compound is: 
O EN / \ O 
30 R -K- N 
35 
wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted aryl; 
and wherein each R" is independently selected from the 
group consisting of hydrogen, optionally Substituted alkyl, 
optionally substituted aryl, halo, OR, NR, SR, CN, COOR, 
CONR, COR, CH(OH)R, and NO. In some preferred 
embodiments, the compound is: 
45 
40 
50 HN \ / 
55 In some preferred embodiments, the compound is: 
=N / \ O 
R- N N & X 
60 N \ / N/ N. y 
NH = 7 (RI): 
65 
wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted aryl; 
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and wherein each R" is independently selected from the 
group consisting of hydrogen, optionally Substituted alkyl, 
optionally substituted aryl, halo, OR, NR, SR, CN, COOR, 
CONR, COR, CH(OH)R, and NO. In some preferred 
embodiments, the compound is: 
EN / V O 
/-K)- v / 
N / v 
NH 
In some embodiments, one or more R. R', R'' or R'' are 
independently halo. In some preferred embodiments, each 
R" is bromo. In some preferred embodiments, each R' is 
fluoro. In some preferred embodiments, the compound is: 
Br / V / \, - - \ / 
N-y 
\ / 
In some preferred embodiments, the compound is: 
The present invention also provides pharmaceutical com 
positions including a compound having any one of the above 
formulas and at least one pharmaceutically acceptable excipi 
ent. 
The present invention also provides use of a compound 
having any one of the above formulas to manufacture a medi 
cament. In some embodiments, the medicament is a medica 
ment for the treatment of a proliferative disorder. The present 
invention also provides a method of treating a proliferative 
disorder by administering a compound having any one of the 
above formulas. 
The present invention also provides a method to identify a 
molecule that modulates protein kinase activity. The method 
includes screening a compound having any one of the above 
formulas to identify a compound having an effect on the 
activity of a protein kinase. 
The present invention also provides a method to treat a 
proliferative disorder. The method includes administering to 
a Subject in need of Such treatment, an effective amount of a 

















R9 R. R. N 
R R 7 
N RR 21 
R 14 N 
R10 \ X-N N-Q 
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R13 
15 R 16 
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(III) 
R9 R2 R3 
R 
EN R 14 N 
R10 \ y-N N-Q /= 
N N s? C 8 R16 V / 
R11 R R7 R 2 R R13 (R'); 
N 
R 15 YR 7 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 
bonded to one or more additional aryl, heterocyclic, or het 
eroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R. R. R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR, S(O)R. 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. In some 
embodiments, the proliferative disorder is a tumor or a cancer 
in a human or animal Subject. In some preferred embodi 
ments, the cancer is selected from the group consisting of 
leukemia, non-Small cell lung cancer, colon cancer, central 
nervous system (CNS) cancer, melanoma, ovarian cancer, 
renal cancer, prostate cancer, and breast cancer. 
The present invention also provides a method to reduce cell 
proliferation. The cells Sometimes are in a cell line. Such as a 
cancer cell line (e.g., breast cancer, prostate cancer, pancre 
atic cancer, lung cancer, hemopoietic cancer, colorectal can 
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cer, skin cancer, ovarian cancer cell line), for example. In 
Some embodiments, the cancer cell line is a leukemia, non 
Small cell lung cancer, colon cancer, central nervous system 
(CNS) cancer, melanoma, ovarian cancer, renal cancer, pros 
tate cancer, or breast cancer cell line. The cells sometimes are 
in a tissue, can be in a Subject, at times are in a tumor, and 
Sometimes are in a tumor in a subject. The method includes 
administering to a cell in an in vitro or in vivo environment, an 
effective amount of a compound of formula (I), (II), or (III): 
(I) 
9 R2 R3 
R R! R4 
N V 
R10 \ X-N N / \ 
N o 
R5 R8 




R9 R2 R3 nN. 
R R4 7 
N Sk RN 21 R 14 N 
R10 \ X-N N-Q 
N (R12) 5 8 ) pi 
R11 R 6 of R iii. 




R9 R2 R3 
S. k" R R =N R 14 N 
R10 \ X-N N-Q /= 
N N s Sos R16 V A 
R11 R R 2 R° R' R13 (R'); 
N 
R15 YR 7 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 
bonded to one or more additional aryl, heterocyclic, or het 
eroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R', and R is independently 
selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R. R. R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR, S(O)R, 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 














The present invention also provides a method to induce cell 
death. The method includes administering to a cell in an in 
vitro or in vivo environment, an effective amount of a com 




N - K. o 
N 




R9 R. R. N 
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(III) 
R9 R2 R3 
R 
N R 14 N 
R10 \ y-N N-Q /= 
N N s s R16 V M 
R11 R R R° R' R13 (R): 
N 
R 15 R17 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 
bonded to one or more additional aryl, heterocyclic, or het 
eroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R. R. R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR, S(O)R. 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
The above methods for reducing cell proliferation and/or 
inducing cell death may also be practiced in combination with 
a procedure and/or a chemotherapeutic agent. Examples of 
procedures that may be used in combination with the methods 
of the present invention include but are not limited to radio 
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therapy or Surgery. In certain embodiments, the compounds 
of the present invention are administered in combination with 
one or more additional compounds, and used to reduce cell 
proliferation, induce cell death, and/or ameliorate a cell pro 
liferative disorder. 
DESCRIPTION OF DRAWING FIGURES 
FIG. 1. Design strategy of compounds 3-6 and 13-24. 
FIG.2. Nonlinear fit curves of the growth inhibitory (MTT 
assay, 48 h treatment) effects of a sample of test compounds 
against A549 (dashed curve) and MCF7 (solid curve) cell 
lines. 
FIG. 3. Dose response curves of compound 4 against four 
selected PDGFR subfamily kinases obtained using the kinase 
binding experiment. A non-linear least Square fit with the 
Levenberg-Marquardt algorithm was implemented to fit the 
curves. WHO-12 denotes for compound 4. The amount of 
DNA-tagged kinase detected by qPCR (Signal; y-axis) is 
plotted versus 4's concentration in nM in log 10 scale 
(X-axis). Data points marked with an “X” were not used for K, 
determination. 
FIG. 4. Dose response curves of compound 4 against 7 
selected PDGFR subfamily kinases obtained using the kinase 
function inhibition screening. The curves were fitted using 
Nonlinear regression (curve fit) implemented in the Graph 
Pad Prism software (version 5.02). A Sigmoidal dose-re 
sponse (variable slope) was used in this case. 
FIG. 5. The overall structure-antiproliferative activity rela 
tionships of piperazinylpyrimidines. 
FIG. 6. The results of the MTT assay in which 4, 15, 16, and 
gefitinib were screened against MDA-MB-468 cell line. (A) 
Dose-response curves against MDA-MB-468 cell line. The 
dose response curves plot the '% viability against the loga 
rithm of the molar concentration. The error bars represent the 
95% confidence interval calculated for 9n (three independent 
experiments, each is a triplicate). (B) IC50 values against 
MDA-MB-468 cell line (uM). The IC50 values were calcu 
lated using non-linear regression analysis as described in the 
experimental section. 
FIG. 7. The percentage of MDA-MB-468 cells in the G2/M 
stage of cell cycle upon treatment with compound 15 at dif 
ferent concentrations and length of time. 
FIG.8. Annexin Vassay results for MDA-MB-468 cells 
treated with compound 15. 
DETAILED DESCRIPTION 
The following description sets forth exemplary methods, 
parameters and the like. It should be recognized, however, 
that such description is not intended as a limitation on the 
Scope of the present proposed invention but is instead pro 
vided as a description of exemplary embodiments. 
1. Definitions 
As used herein, the terms “alkyl.” “alkenyl and “alkynyl 
include straight-chain, branched-chain and cyclic monova 
lent hydrocarbyl radicals, and combinations of these, which 
contain only C and H when they are unsubstituted. Examples 
include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 
2-propenyl, 3-butynyl, and the like. The total number of car 
bonatoms in each Such group is sometimes described herein, 
e.g., when the group can contain up to ten carbonatoms it can 
be represented as 1-10C or as C1-C10 or C1-C10. When 
heteroatoms (N, O and S typically) are allowed to replace 













bers describing the group, though still written as e.g. C1-C6, 
represent the Sum of the number of carbon atoms in the group 
plus the number of such heteroatoms that are included as 
replacements for carbon atoms in the ring or chain being 
described. 
Typically, the alkyl, alkenyl and alkynyl substituents of the 
invention contain 1-10C (alkyl) or 2-10C (alkenyl oralkynyl). 
Preferably they contain 1-8C (alkyl) or 2-8C (alkenyl or alky 
nyl). Sometimes they contain 1-4C (alkyl) or 2-4C (alkenyl or 
alkynyl). A single group can include more than one type of 
multiple bond, or more than one multiple bond; Such groups 
are included within the definition of the term “alkenyl' when 
they contain at least one carbon-carbon double bond, and are 
included within the term “alkynyl' when they contain at least 
one carbon-carbon triple bond. 
Alkyl, alkenyl and alkynyl groups are often substituted to 
the extent that Such Substitution makes sense chemically. 
Typical substituents include, but are not limited to, halo, =O. 
=N CN, =N OR, =NR, OR, NR, SR, S(O)R, SOR, 
SONR, NRSOR, NRCONR, NRCOOR, NRCOR, CN, 
COOR, CONR, OOCR, COR, CH(OH)R, and NO, wherein 
each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, 
C3-C8 heterocyclyl, C4-C10 heterocyclyclalkyl, C1-C8 acyl, 
C2-C8 heteroacyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, 
C2-C8 alkynyl, C2-C8 heteroalkynyl, C6-C10 aryl, or 
C5-C10 heteroaryl, and each R is optionally substituted with 
halo, =O, —N CN, =N OR", =NR', OR, NR', SR', 
SOR', SONR, NR'SOR, NRCONR, NRCOOR, 
NRCOR, CN, COOR, CONR, OOCR, COR', and NO, 
wherein each R" is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C3-C8 heterocyclyl, C4-C10 heterocyclyclalkyl, 
C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl or C5-C10 het 
eroaryl. Alkyl, alkenyl and alkynyl groups can also be substi 
tuted by C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl or 
C5-C10 heteroaryl, each of which can be substituted by the 
Substituents that are appropriate for the particular group. 
Where a substituent group contains two R or R' groups on the 
same or adjacent atoms (e.g., —NR, or—NR—C(O)R), the 
two R or R' groups can optionally be taken together with the 
atoms in the Substituent group to which the are attached to 
form a ring having 5-8 ring members, which can be substi 
tuted as allowed for the R or R' itself, and can contain an 
additional heteroatom (N, O or S) as a ring member. 
“Heteroalkyl, "heteroalkenyl', and "heteroalkynyl and 
the like are defined similarly to the corresponding hydrocar 
byl (alkyl, alkenyl and alkynyl) groups, but the hetero terms 
refer to groups that contain 1-3O, S or N heteroatoms or 
combinations thereof within the backbone residue; thus at 
least one carbon atom of a corresponding alkyl, alkenyl, or 
alkynyl group is replaced by one of the specified heteroatoms 
to form a heteroalkyl, heteroalkenyl, or heteroalkynyl group. 
The typical and preferred sizes for heteroforms of alkyl, alk 
enyl and alkynyl groups are generally the same as for the 
corresponding hydrocarbyl groups, and the Substituents that 
may be present on the heteroforms are the same as those 
described above for the hydrocarbyl groups. For reasons of 
chemical stability, it is also understood that, unless otherwise 
specified. Such groups do not include more than two contigu 
ous heteroatoms except where an oxo group is present on Nor 
S as in a nitro or Sulfonyl group. 
While “alkyl as used herein includes cycloalkyl and 
cycloalkylalkyl groups, the term "cycloalkyl may be used 
herein to describe a carbocyclic non-aromatic group that is 
connected via a ring carbon atom, and “cycloalkylalkyl may 
be used to describe a carbocyclic non-aromatic group that is 
connected to the molecule through an alkyl linker. Similarly, 
"heterocyclyl may be used to describe a non-aromatic cyclic 
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group that contains at least one heteroatom as a ring member 
and that is connected to the molecule via a ring atom, which 
may be C or N; and "heterocyclylalkyl may be used to 
describe Such a group that is connected to another molecule 
through a linker. The sizes and substituents that are suitable 
for the cycloalkyl, cycloalkylalkyl, heterocyclyl, and hetero 
cyclylalkyl groups are the same as those described above for 
alkyl groups AS used herein, these terms also include rings 
that contain a double bond or two, as long as the ring is not 
aromatic. 
As used herein, “acyl encompasses groups comprising an 
alkyl, alkenyl, alkynyl, aryl or arylalkyl radical attached at 
one of the two available valence positions of a carbonyl car 
bonatom, and heteroacyl refers to the corresponding groups 
wherein at least one carbon other than the carbonyl carbon has 
been replaced by a heteroatom chosen from N, O and S. Thus 
heteroacyl includes, for example, —C(=O)CR and 
—C(=O)NR as well as —C(=O)-heteroaryl. 
Acyl and heteroacyl groups are bonded to any group or 
molecule to which they are attached through the open Valence 
of the carbonyl carbon atom. Typically, they are C1-C8 acyl 
groups, which include formyl, acetyl, pivaloyl, and benzoyl, 
and C2-C8 heteroacyl groups, which include methoxyacetyl, 
ethoxycarbonyl, and 4-pyridinoyl. The hydrocarbyl groups, 
aryl groups, and heteroforms of such groups that comprise an 
acyl or heteroacyl group can be substituted with the substitu 
ents described herein as generally suitable substituents for 
each of the corresponding component of the acyl or heteroa 
cyl group. 
“Aromatic' moiety or “aryl moiety refers to a monocyclic 
or fused bicyclic moiety having the well-known characteris 
tics of aromaticity; examples include phenyl and naphthyl. 
Similarly, "heteroaromatic' and "heteroaryl' refer to such 
monocyclic or fused bicyclic ring systems which contain as 
ring members one or more heteroatoms selected from O. S 
and N. The inclusion of a heteroatom permits aromaticity in 
5-membered rings as well as 6-membered rings. Typical het 
eroaromatic systems include monocyclic C5-C6 aromatic 
groups such as pyridyl, pyrimidyl, pyrazinyl, thienyl, furanyl. 
pyrrolyl pyrazolyl, thiazolyl, oxazolyl, and imidazolyl and 
the fused bicyclic moieties formed by fusing one of these 
monocyclic groups with a phenyl ring or with any of the 
heteroaromatic monocyclic groups to form a C8-C10 bicyclic 
group Such as indolyl, benzimidazolyl, indazolyl, benzotria 
Zolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl. 
pyrazolopyridyl, quinazolinyl, quinoxalinyl, cinnolinyl, and 
the like. Any monocyclic or fused ring bicyclic system which 
has the characteristics of aromaticity in terms of electron 
distribution throughout the ring system is included in this 
definition. It also includes bicyclic groups where at least the 
ring which is directly attached to the remainder of the mol 
ecule has the characteristics of aromaticity. Typically, the ring 
systems contain 5-12 ring member atoms. Preferably the 
monocyclic heteroaryls contain 5-6 ring members, and the 
bicyclic heteroaryls contain 8-10 ring members. 
Aryl and heteroaryl moieties may be substituted with a 
variety of substituents including C1-C8 alkyl, C2-C8 alkenyl, 
C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C12 aryl, C1-C8 acyl, 
and heteroforms of these, each of which can itself be further 
substituted; other substituents for aryl and heteroaryl moi 
eties include halo, OR, NR, SR, S(O)R, SOR, SONR, 
NRSOR, NRCONR, NRCOOR, NRCOR, CN, COOR, 
CONR, OOCR, COR, CH(OH)R, and NO, wherein each R 
is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 
alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het 
eroalkynyl, C3-C8 heterocyclyl, C4-C10 heterocyclyclalkyl, 
C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or 
C6-C12 heteroarylalkyl, and each R is optionally substituted 













group contains two R or R' groups on the same or adjacent 
atoms (e.g., —NR2, or —NR—C(O)R), the two R or R' 
groups can optionally be taken together with the atoms in the 
Substituent group to which the are attached to form a ring 
having 5-8 ring members, which can be substituted as allowed 
for the Ror R' itself, and can contain an additional heteroatom 
(N, O or S) as a ring member. The Substituent groups on an 
aryl or heteroaryl group may of course be further substituted 
with the groups described herein as suitable for each type of 
Such substituents or for each component of the Substituent. 
Thus, for example, an arylalkyl Substituent may be substi 
tuted on the aryl portion with substituents described hereinas 
typical for aryl groups, and it may be further Substituted on 
the alkyl portion with substituents described herein as typical 
or Suitable for alkyl groups. 
Similarly, “arylalkyl and "heteroarylalkyl refer to aro 
matic and heteroaromatic ring systems which are bonded to 
their attachment point through a linking group Such as an 
alkylene, including Substituted or unsubstituted, Saturated or 
unsaturated, cyclic or acyclic linkers. Typically the linker is 
C1-C8 alkyl or a hetero form thereof. These linkers may also 
include a carbonyl group, thus making them able to provide 
Substituents as an acyl or heteroacyl moiety. An aryl or het 
eroaryl ring in an arylalkyl or heteroarylalkyl group may be 
substituted with the same substituents described above for 
aryl groups. Preferably, an arylalkyl group includes a phenyl 
ring optionally substituted with the groups defined above for 
aryl groups and a C1-C4 alkylene that is unsubstituted or is 
substituted with one or two C1-C4 alkyl groups or heteroalkyl 
groups, where the alkyl or heteroalkyl groups can optionally 
cyclize to form a ring such as cyclopropane, dioxolane, or 
oxacyclopentane. Similarly, a heteroarylalkyl group prefer 
ably includes a C5-C6 monocyclic heteroaryl group that is 
optionally substituted with the groups described above as 
Substituents typical on aryl groups and a C1-C4 alkylene that 
is unsubstituted or is substituted with one or two C1-C4 alkyl 
groups or heteroalkyl groups, or it includes an optionally 
substituted phenyl ring or C5-C6 monocyclic heteroaryland 
a C1-C4 heteroalkylene that is unsubstituted or is substituted 
with one or two C1-C4 alkyl or heteroalkyl groups, where the 
alkyl or heteroalkyl groups can optionally cyclize to form a 
ring Such as cyclopropane, dioxolane, or oxacyclopentane. 
Where an arylalkyl or heteroarylalkyl group is described as 
optionally substituted, the substituents may be on either the 
alkyl or heteroalkyl portion or on the aryl or heteroaryl por 
tion of the group. The Substituents optionally present on the 
alkyl or heteroalkyl portion are the same as those described 
above for alkyl groups generally; the Substituents optionally 
present on the aryl or heteroaryl portion are the same as those 
described above for aryl groups generally. 
"Arylalkyl groups as used herein are hydrocarbyl groups 
if they are unsubstituted, and are described by the total num 
ber of carbonatoms in the ring and alkylene or similar linker. 
Thus a benzyl group is a C7-arylalkyl group, and phenylethyl 
is a C8-arylalkyl. 
“Heteroarylalkyl as described above refers to a moiety 
comprising an aryl group that is attached through a linking 
group, and differs from “arylalkyl in that at least one ring 
atom of the aryl moiety or one atom in the linking group is a 
heteroatom selected from N, O and S. The heteroarylalkyl 
groups are described herein according to the total number of 
atoms in the ring and linker combined, and they include aryl 
groups linked through a heteroalkyl linker, heteroaryl groups 
linked through a hydrocarbyl linker Such as an alkylene; and 
heteroaryl groups linked through a heteroalkyl linker. Thus, 
for example, C7-heteroarylalkyl would include pyridylm 
ethyl, phenoxy, and N-pyrrolylmethoxy. 
Alkylene' as used herein refers to a divalent hydrocarbyl 
group; because it is divalent, it can link two other groups 
together. Typically it refers to —(CH), where n is 1-8 and 
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preferably n is 1-4, though where specified, an alkylene can 
also be substituted by other groups, and can be of other 
lengths, and the open Valences need not be at opposite ends of 
a chain. Thus —CH(Me)- and —C(Me)- may also be 
referred to as alkylenes, as can a cyclic group Such as cyclo 
propan-1,1-diyl. Where an alkylene group is Substituted, the 
Substituents include those typically present on alkyl groups as 
described herein. 
In general, any alkyl, alkenyl, alkynyl, acyl, or aryl or 
arylalkyl group or any heteroform of one of these groups that 
is contained in a Substituent may itself optionally be substi 
tuted by additional substituents. The nature of these substitu 
ents is similar to those recited with regard to the primary 
substituents themselves if the substituents are not otherwise 
described. Thus, where an embodiment of, for example, R is 
alkyl, this alkyl may optionally be substituted by the remain 
ing substituents listed as embodiments for R' where this 
makes chemical sense, and where this does not undermine the 
size limit provided for the alkyl perse; e.g., alkyl substituted 
by alkyl or by alkenyl would simply extend the upper limit of 
carbon atoms for these embodiments, and is not included. 
However, alkyl substituted by aryl, amino, alkoxy, —O, and 
the like would be included within the scope of the invention, 
and the atoms of these Substituent groups are not counted in 
the number used to describe the alkyl, alkenyl, etc. group that 
is being described. Where no number of substituents is speci 
fied, each Such alkyl, alkenyl, alkynyl, acyl, oraryl group may 
be substituted with a number of substituents according to its 
available Valences; in particular, any of these groups may be 
substituted with fluorine atoms at any or all of its available 
Valences, for example. 
“Heteroform' as used herein refers to a derivative of a 
group Such as an alkyl, aryl, or acyl, wherein at least one 
carbon atom of the designated carbocyclic group has been 
replaced by a heteroatom selected from N, O and S. Thus the 
heteroforms of alkyl, alkenyl, alkynyl, acyl, aryl, and aryla 
lkyl are heteroalkyl, heteroalkenyl, heteroalkynyl, heteroa 
cyl, heteroaryl, and heteroarylalkyl, respectively. It is under 
stood that no more than two N, O or Satoms are ordinarily 
connected sequentially, except where an oxo group is 
attached to N or S to form a nitro or sulfonyl group. 
"Optionally substituted as used herein indicates that the 
particular group or groups being described may have no non 
hydrogen Substituents, or the group or groups may have one 
or more non-hydrogen Substituents. If not otherwise speci 
fied, the total number of such substituents that may be present 
is equal to the number of Hatoms present on the unsubstituted 
form of the group being described. Where an optional sub 
stituent is attached via a double bond. Such as a carbonyl 
oxygen (=O), the group takes up two available Valences, so 
the total number of substituents that may be included is 
reduced according to the number of available valences. 
"Halo' as used herein includes fluoro, chloro, bromo and 
iodo. 
Amino” as used herein refers to NH, but where an amino 
is described as “substituted” or “optionally substituted, the 
term includes NR'R'" wherein each RandR" is independently 
H, or is an alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl 
group or a heteroform of one of these groups, and each of the 
alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl groups or het 
eroforms of one of these groups is optionally substituted with 
the substituents described herein as suitable for the corre 
sponding group. The term also includes forms wherein Rand 
R" are linked together to form a 3-8 membered ring which 
may be saturated, unsaturated or aromatic and which contains 
1-3 heteroatoms independently selected from N, O and S as 














substituents described as suitable for alkyl groups or, if 
NRR" is an aromatic group, it is optionally substituted with 
the Substituents described as typical for heteroaryl groups. 
In many compounds within the present invention, isomers 
including double bond isomers, restricted rotation isomers, 
optical isomers, and mixtures of these are possible. The 
invention includes each individual isomeras well as mixtures 
of various isomeric forms, and specifically includes racemic 
mixtures as well as individual enantiomers where a single 
chiral carbon is present. Where multiple chiral carbons are 
present, each individual diastereomer is included as well as 
mixtures that comprise a racemic mixture of one or more 
diastereomer. Many of the compounds herein can exist in 
different tautomeric forms, and it is understood that each 
tautomer is included within the scope of the invention as well. 
The terms “treat,” “treatment” and “therapeutic effect” as 
used herein refer to reducing or stopping a cell proliferation 
rate (e.g., slowing or halting tumor growth), reducing the 
number of proliferating cancer cells (e.g., removing part orall 
of a tumor), or ameliorating a cell-proliferative disorder in a 
human or animal Subject. 
The terms “cell-proliferative disorder,” or “proliferative 
disorder as used herein refers to a tumor or a cancer in a 
human or animal Subject. In non-limiting embodiments, the 
cancer is leukemia, non-Small cell lung cancer, colon cancer, 
central nervous system (CNS) cancer, melanoma, ovarian 
cancer, renal cancer, prostate cancer, or breast cancer. 
2. Description of the Invention 
The present invention relates to piperzinylpyrimidine com 
pounds having formulas (I), (II), or (III), and pharmaceuti 
cally acceptable salts, esters, and prodrugs thereof. The 
present invention also relates to methods for using the com 
pounds described herein, Such as in screening and in treat 
ment and in the preparation of a medicament or pharmaceu 
tical composition for treating conditions described herein. 
The compounds of the present invention may or may not 
interact with hinge region and/or ATP-binding groove. Can 
didate compounds were identified using anticancer cellular 
assays as a first screen followed by biochemical investigation 
of those compounds with encouraging cellular activity pro 
files. Such an order of experiments may aid in identifying 
cytotoxic or cytostatic lead compounds which may fail to 
interact with their intended targets and happen to interact with 
another protein family that was not anticipated. In the current 
investigation, a systematic attachment of a quinazoline ring, 
known as a kinase privileged fragment, to a piperazinylpyri 
midine Scaffold, through linkers that positionaforementioned 
fragments in different relative orientations, has been adopted 
as a strategy to discover new and selective prototype kinase 
inhibitors. 
The compounds of the present invention having formulas 
(I), (II), or (III) are reproduced below: 
(I) 
R9 R R3 4 
"Sk" - N N 
R10 \ X-N N / \ 
N R5 R8 o 
R11 R6 R7 
(R12) 
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(III) 
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R 
=N R 14 N 
R10 \ y-N N-Q /= 
N N s Sos R16 W A 
R11 R R7 R 2 R R13 (R'); 
N 
R 15 YR 7 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 
bonded to one or more additional aryl, heterocyclic, or het 
eroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R', and R is independently 
selected from hydrogen, optionally substituted alkyl, or 
optionally substituted aryl; 
each R, R', R'', R. R. R. R' and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR, S(O)R. 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted, with the proviso that R' for formula 
(I) must not be hydrogen; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
The compounds of the present invention may be chiral. As 
used herein, a chiral compound is a compound that is different 
from its mirror image, and has an enantiomer. Furthermore, 
the compounds may be racemic, or an isolated enantiomer or 
Stereoisomer. Methods of synthesizing chiral compounds and 
resolving a racemic mixture ofenantiomers are well knownto 
those skilled in the art. See, e.g., March, Advanced Organic 
Chemistry, John Wiley and Sons, Inc., New York, (1985). 
Compound Synthesis 
Synthetic procedures for preparing the compounds of the 
present invention are illustrated in Schemes 1 and 2 and in the 
Examples. Other variations in the synthetic procedures 
known to those with ordinary skill in the art may also be used 
to prepare the compounds of the present invention. The com 
pounds are then isolated and purified by conventional meth 
ods. The compounds also may be made as or converted into 
salts, and in certain embodiments they are made and used as 














The piperizinylpyrimidine compounds of the present 
invention were designed to target the human kinome via 
linking of a piperazinylprimidine core with a quinazoline 
group either directly, as in group I, or through an orientation 
linker, group II, which may offer more rigidity (n=0) or more 
flexibility (n=1) (FIG. 1). Though not limiting the invention 
by any theory, the designed derivatives were tailored to poten 
tially localize the hinge region of kinases via their kinase 
privileged fragment and extend either through the ATP-bind 
ing groove or towards the adjacent allosteric site so as to be 
either type-I or type-II inhibitors, respectively, or perhaps 
even adopt a novel binding mode. There are two major ration 
ales upon which this design strategy is based: i) because a 
wide range of conformational ensembles of both active and 
inactive states exist among the 518 human kinases, certain 
kinases may be able to accommodate the piperazinylpyrimi 
dine Scaffold attached to the quinazoline moiety; and ii) 
exploiting the steric space of a given class of small molecules 
with similar chemical features that are positioned differently 
within the binding site may generate more than one lead 
kinase inhibitor with different respective kinase selectivity 
profiles and/or anticancer cellular activity. 
The final compounds were mainly derived from two major 
piperazinylpyrimidine key intermediates (Schemes 1 and 2: 
Examples 1 and 2). Intermediate 1 was reported in the litera 
ture, and the deprotection step was performed using HCl/ 
MeOH method (Betschart, C. et al. US 2005/0054851 A1, 
2005). Intermediate 2 was synthesized using palladium cata 
lyZed Suzuki cross coupling followed by deprotection as 
illustrated in Scheme 2. 
Scheme 1 
-O-(S (a) TEA, EtOH, reflux -e-(b) HCI/MeOH, rt 
(a) K2CO3, Pd(PPh3)4, THF/H2O, 
100-110° C. 
(b) HCI/MeOH, rt 
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Group I compounds 3-6 (see Examples 3-6) were prepared 
directly by allowing the respective 4-chloroquinazoline 
derivative to react with one of the piperazinylpyrimidine 
intermediates (Scheme 3). Group I compounds represent the 
direct attachment between the ATP-binding site localizing 
quinazoline fragment and the selectivity inducing piperazi 
nylpyrimidine scaffold. Intermediates 7-12 (see Examples 
7-12) were synthesized by allowing m-aminobenzoic acid, 
p-aminobenzoic acid; or p-aminomethylbenzoic acid to react 
with the corresponding quinazoline derivative using similar 
reaction conditions to those implemented in preparing group 
I compounds (Scheme 4). Scheme 4 demonstrates the con 
nection of the quinazoline fragment with the different linkers 
implemented for group II compounds 13-24 (see Examples 
13-24). Group II derivatives were prepared via coupling the 
carboxylic acid group of the intermediates (7-12) with the 
secondary aliphatic amine functionality of either intermedi 
ate 1 or intermediate 2 using EDC/HCl and triethylamine 
mixture as outlined in Scheme 5. Group II is structurally 
different from group I via the incorporation of a linker 
between the two major fragments. Such a linker strategy 
offers three different options; m-aminophenylcarbonyl and 
p-aminophenylcarbonyl provide similar rigidity level while 
orienting the fragments differently whereas p-aminometh 
ylphenylcarbonyl provides more flexibility that allows the 
compound to cover more conformational space in orienting 
the major fragments. 
Scheme 3 
/ \ -- N C 
)=n 
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R = H, C6H5 
/ \ N Isopropanol, 
/ \ TEA 
HN N He 
V / 80° C., 1.5 h 
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1-2 
1: R2 CH3 
2: R = CHs 
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3-6 
3: R = H, R2 = CH 
4: R H, R2 C6H5 
5: R1 = CH5, R = CH3 








































meta, n = 0, R = H 
para, n = 1, R = H 
meta, n = 0, R1 = CH5 
para, n = 0, R1 = CHs 
para, n = 1, R1 = C5H5 








80° C., 1.5 h 
3-10 
: meta, n = 0, R = H 
: para, n = 0, R = H 
: para, n = 1, R = H 
: meta, n = 0, R1 = C5H5 
para, n = 0, R1 = C6Hs 










21 } O -( ) R2 
13-24 
meta, n = 0, R = H, R2 = CH3 19: meta, n = 0, R1 = C6H5, R2 = CH3 
para, n = 0, R = H, R = CH3 20: para, n = 0, R1 = CH5, R = CH3 
para, n = 1, R = H 21: para, n = 1, R1 = CH5, R = CH3 
meta, n = 0, R = H, R2 = C5H5 22: meta, n = 0, R1 = C6H5, R2 = C5H5 
para, n = 0, , R = CHs 23: para, n = 0, R1 = CH5, R = CH5 







The compounds of the present invention may be designed 
to be more resistant to metabolism compared by incorporat 
ingahalo substituent at one or more of the R. R', R'', or R' 
Substituents. For example, compounds 25 and 26 were Syn 
thesized according to Examples 25 and 26, below. Each of 
compounds 25 and 26 incorporate one—Br substituent at the 
R" position and one —F substituent at one of the R' posi 
tions. 
Formulation of Compounds 
As used herein, the term “pharmaceutically acceptable 
salts, esters and amides' includes but are not limited to car 
boxylate salts, amino acid addition salts, esters and amides of 
the compounds, as well as the Zwitterionic forms thereof, 
which are known to those skilled in the art as suitable for use 
with humans and animals. (See, e.g., Berge, S. M., et al., 
“Pharmaceutical Salts.” J. Pharm. Sci. (1977) 66:1-19, which 
is incorporated herein by reference.) 
Any suitable formulation of the compounds described 
herein can be prepared using carriers and excipients that are 
well known in the art for use in a particular application. For 
example, compounds may be admixed with a carrier for use in 
in vitro or in vivo applications. Suitable carriers include par 
tially purified water, Such as deionized water or an isotonic 
Solution; buffer systems such as bicarbonate, phosphate, and 
similar buffers; and mixtures of aqueous solutions with 
water-miscible organic cosolvents such as acetone or DMSO. 
Phosphate-buffered saline (PBS), which may be buffered to 
provide a neutral pH, or in certain embodiments an acidic pH, 
is sometimes preferred. Stabilizing agents may also be 
included. 
In cases where compounds are sufficiently basic or acidic 
to form stable nontoxic acid or base salts, administration of 
the compounds as salts may be appropriate. Examples of 
pharmaceutically acceptable salts are organic acid addition 
salts formed with acids that form a physiological acceptable 
anion, for example, tosylate, methanesulfonate, acetate, cit 
rate, malonate, tartarate. Succinate, benzoate, ascorbate, 
C.-ketoglutarate, and O-glycerophosphate. Suitable inorganic 
salts may also be formed, including hydrochloride, Sulfate, 
nitrate, bicarbonate, and carbonate salts. Pharmaceutically 
acceptable salts are obtained using standard procedures well 
known in the art. For example, pharmaceutically acceptable 
salts may be obtained by reacting a sufficiently basic com 













physiologically acceptable anion. Alkali metal (e.g., Sodium, 
potassium or lithium) or alkaline earth metal (e.g., calcium, 
magnesium) salts of carboxylic acids and other anionic 
groups in molecules within the invention also are contem 
plated. 
A compound may be formulated as a pharmaceutical com 
position and administered to a mammalian host in need of 
Such treatment. Forpharmaceutical applications, a compound 
is typically combined with a pharmaceutically acceptable 
carrier Such as water or other pharmaceutically acceptable 
excipients. In one embodiment, the mammalian host is 
human. Any Suitable route of administration may be used, 
including but not limited to oral, parenteral, intravenous, 
intramuscular, topical and Subcutaneous routes. 
In one embodiment, a compound is administered systemi 
cally (e.g., orally) in combination with a pharmaceutically 
acceptable vehicle Such as an inert diluent or an assimilable 
edible carrier. They may be enclosed in hard or soft shell 
gelatin capsules, compressed into tablets, or incorporated 
directly with the food of the patients diet. For oral therapeu 
tic administration, the active compound may be combined 
with one or more excipients and used in the form of ingestible 
tablets, buccal tablets, troches, capsules, elixirs, Suspensions, 
syrups, wafers, and the like. Such compositions and prepara 
tions should contain at least 0.1% of active compound. The 
percentage of the compositions and preparations may be var 
ied and may conveniently be between about 2 to about 60% of 
the weight of a given unit dosage form. The amount of active 
compound in Such therapeutically useful compositions is 
such that an effective dosage level will be obtained. 
Tablets, troches, pills, capsules, and the like also may con 
tain the following: binders such as gum tragacanth, acacia, 
corn starch or gelatin; excipients such as dicalcium phos 
phate; a disintegrating agent such as corn starch, potato 
starch, alginic acid and the like; a lubricant Such as magne 
sium Stearate; and a Sweetening agent such as Sucrose, fruc 
tose, lactose or aspartame or a flavoring agent such as pep 
permint, oil of wintergreen, orcherry flavoring may be added. 
When the unit dosage form is a capsule, it may contain, in 
addition to materials of the above type, a liquid carrier, Such 
as a vegetable oil or a polyethylene glycol. Various other 
materials may be present as coatings or to otherwise modify 
the physical form of the Solid unit dosage form. For instance, 
tablets, pills, or capsules may be coated with gelatin, wax, 
shellac or Sugar and the like. A syrup or elixir may contain the 
active compound. Sucrose or fructose as a Sweetening agent, 
methyl and propylparabens as preservatives, a dye and fla 
Voring Such as cherry or orange flavor. Any material used in 
preparing any unit dosage form is pharmaceutically accept 
able and Substantially non-toxic in the amounts employed. In 
addition, the active compound may be incorporated into Sus 
tained-release preparations and devices. 
The active compound also may be administered intrave 
nously or intraperitoneally by infusion or injection. Solutions 
of the active compound or its salts may be prepared in a 
buffered solution, optionally mixed with a nontoxic surfac 
tant. Dispersions can also be prepared in glycerol, liquid 
polyethylene glycols, triacetin, and mixtures thereof and in 
oils. Under ordinary conditions of storage and use, these 
preparations contain a preservative to prevent the growth of 
microorganisms 
The pharmaceutical dosage forms suitable for injection or 
infusion can include sterile aqueous solutions or dispersions 
or sterile powders comprising the active ingredient that are 
adapted for the extemporaneous preparation of sterile inject 
able or infusible solutions or dispersions, optionally encap 
Sulated in liposomes. In all cases, the ultimate dosage form 
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should be sterile, fluid and stable under the conditions of 
manufacture and storage. The liquid carrier or vehicle can be 
a solvent or liquid dispersion medium comprising, for 
example, water, ethanol, a polyol (for example, glycerol, 
propylene glycol, liquid polyethylene glycols, and the like), 
Vegetable oils, nontoxic glyceryl esters, and Suitable mixtures 
thereof. The proper fluidity can be maintained, for example, 
by the formation of liposomes, by the maintenance of the 
particle size in the case of dispersions or by the use of Surfac 
tants. The prevention of the action of microorganisms can be 
brought about by various antibacterial and antifungal agents, 
for example, parabens, chlorobutanol, phenol, Sorbic acid, 
thimerosal, and the like. In many cases, it will be preferable to 
include isotonic agents, for example, Sugars, buffers or 
sodium chloride. Prolonged absorption of the injectable com 
positions can be brought about by the use in the compositions 
of agents delaying absorption, for example, aluminum 
monostearate and gelatin. 
Sterile injectable solutions are prepared by incorporating 
the active compound in the required amount in the appropri 
ate solvent with various of the other ingredients enumerated 
above, as required, followed by filter sterilization. In the case 
of sterile powders for the preparation of sterile injectable 
Solutions, the preferred methods of preparation are vacuum 
drying and the freeze drying techniques, which yield a pow 
der of the active ingredient plus any additional desired ingre 
dient present in the previously sterile-filtered solutions. 
For topical administration, the present compounds may be 
applied in liquid form. Compounds often are administered as 
compositions or formulations, in combination with a derma 
tologically acceptable carrier, which may be a solid or a 
liquid. Examples of useful dermatological compositions used 
to deliver compounds to the skin are known (see, e.g., Jac 
quet, et al. (U.S. Pat. No. 4,608.392), Geria (U.S. Pat. No. 
4,992.478), Smith, et al. (U.S. Pat. No. 4,559,157) and Wortz 
man (U.S. Pat. No. 4,820,508). 
Compounds may be formulated with a solid carrier, which 
include finely divided Solids such as talc, clay, microcrystal 
line cellulose, silica, alumina and the like. Useful liquid car 
riers include water, alcohols or glycols or water-alcohol/gly 
col blends, in which the present compounds can be dissolved 
or dispersed at effective levels, optionally with the aid of 
non-toxic Surfactants. Adjuvants such as fragrances and addi 
tional antimicrobial agents can be added to optimize the prop 
erties for a given use. The resultant liquid compositions can 
be applied from absorbent pads, used to impregnate bandages 
and other dressings, or sprayed onto the affected area using 
pump-type or aerosol sprayers. Thickeners such as synthetic 
polymers, fatty acids, fatty acid salts and esters, fatty alco 
hols, modified celluloses or modified mineral materials can 
also be employed with liquid carriers to form spreadable 
pastes, gels, ointments, soaps, and the like, for application 
directly to the skin of the user. 
Generally, the concentration of the compound in a liquid 
composition often is from about 0.1 wt % to about 25 wt %, 
sometimes from about 0.5 wt % to about 10 wt %. The 
concentration in a semi-solid or solid composition Such as a 
gel or a powder often is about 0.1 wt % to about 5 wt %, 
sometimes about 0.5 wt % to about 2.5 wt %. Higher concen 
trations are also appropriate for Some solid or semi-solid 
compositions, and may include amounts up to about 25 wt % 
or up to about 50 wt % or more. A compound composition 
may be prepared as a unit dosage form, which is prepared 
according to conventional techniques known in the pharma 
ceutical industry. In general terms, such techniques include 













carrier(s) and/or excipient(s) in liquid form or finely divided 
Solid form, or both, and then shaping the product if required. 
Methods 
The present invention provides a method to identify a mol 
ecule that modulates protein kinase activity. The method 
includes screening a compound described herein, to identify 
a compound having an effect on the activity of a protein 
kinase. 
The present invention also provides a method to treat a 
proliferative disorder. The method includes administering to 
a Subject in need of Such treatment, an effective amount of a 
compound of formula (I), (II), or (III): 
(I) 
R! R Xy. 
N - K. R8 
4 
N 




R9 R. R. N 
R R 7 
N Sk RS 21 R 14 
R10 \ X-N N-Q 
N (R12) 
R11 R5 6 R8 m pi 
R. R. 13 R 
15 R 16 
R 
(III) 
R9 R2 R3 
R 
=N R 14 N 
R10 \ X-N N-Q /= 
N N s so R16 V A 
R11 R R 2 R° R' R13 (R'); 
N 
R 15 YR 7 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 
bonded to one or more additional aryl, heterocyclic, or het 
eroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R, R', R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR, S(O)R. 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted; and 
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each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
The present invention also provides a method to treat a 
proliferative disorder. In some embodiments, the proliferative 
disorder is a tumor or a cancer in a human or animal Subject. 
In Some preferred embodiments, the cancer may be leukemia, 
lung cancer, non-Small cell lung cancer, hemopoietic cancer, 
colorectal cancer, colon cancer, skin cancer, central nervous 
system (CNS) cancer, melanoma, ovarian cancer, renal can 
cer, prostate cancer, ovarian cancer, or breast cancer. In some 
preferred embodiments, the cancer may be leukemia, non 
Small cell lung cancer, colon cancer, central nervous system 
(CNS) cancer, melanoma, ovarian cancer, renal cancer, pros 
tate cancer, or breast cancer. 
The present invention also provides a method to reduce cell 
proliferation. The cells Sometimes are in a cell line. Such as a 
cancer cell line (e.g., breast cancer, prostate cancer, pancre 
atic cancer, lung cancer, hemopoietic cancer, colorectal can 
cer, skin cancer, ovarian cancer cell line), for example. In 
Some embodiments, the cancer cell line is a leukemia, non 
Small cell lung cancer, colon cancer, central nervous system 
(CNS) cancer, melanoma, ovarian cancer, renal cancer, pros 
tate cancer, or breast cancer cell line. The cells sometimes are 
in a tissue, can be in a Subject, at times are in a tumor, and 
Sometimes are in a tumor in a subject. The method includes 
administering to a cell in an in vitro or in vivo environment, an 
effective amount of a compound of formula (I), (II), or (III): 
(I) 
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wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 














each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R. R. R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR; S(O)R. 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
A compound having any one of the above formulas may 
also be used in methods to induce cell death. The method 
includes administering to a cell in an in vitro or in vivo 
environment, an effective amount of a compound of formula 
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wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with or 
bonded to one or more additional aryl, heterocyclic, or het 
eroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R', and R is independently 
selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
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each R, R', R'', R', R', R', R', and R' is indepen 
dently selected from hydrogen, optionally Substituted alkyl, 
or optionally substituted aryl, halo, OR, NR, SR, S(O)R. 
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO, 
wherein each R is independently H, C1-C8 alkyl, C2-C8 
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is 
optionally substituted; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
The compounds of the present invention may be used for 
research purposes, as the compounds show overall selectivity 
towards certain kinase Subfamilies. The compounds may be 
used to identify the efficacy of modulating kinase activity of 
certain combinations of kinase subfamilies in cells. The 
present invention also provides a composition comprising an 
isolated protein kinase complexed with a compound of for 
mula (I), (II), or (III). Such complexes are useful for the 
information they provide about the binding site of a modu 
lating compound to the particular kinase, and as a research 
tool for analyzing the structure of the kinase. Such complexes 
are also useful because they may be more readily crystallized 
than the uncomplexed kinase, allowing crystallization and 
crystal structure determination where it would not be possible 
without the bound modulating compound. 
EXAMPLES 
The following examples are offered to illustrate but not to 
limit the invention. 
General Chemistry 
All temperatures are expressed in C. (degrees centigrade). 
All reagents, solvents, and starting materials were obtained 
from commercial suppliers and used without further purifi 
cation. Reactions requiring anhydrous conditions were per 
formed in dry solvents under Argon atmosphere. Reactions 
were monitored by thin layer chromatography (TLC) on pre 
coated silica gel F254 plates (EMD) using a UV detector for 
visualization. Flash column chromatography was performed 
with EMD 230-400 mesh silica gel 60 A. Yields are of puri 
fied products. Melting points were determined using Thomas 
Hoover melting point apparatus and are uncorrected. "H 
NMR and 'C NMR spectra were recorded on a Jeol JNM 
ECA600 spectrometer. The obtained FID of each experiment 
was processed using Delta NMRID processor software. The 
chemical shifts are expressed in parts per million (ppm) down 
field from TMS. Spin multiplicities are designated as s (sin 
glet), d (doublet), dd (doublet of doublets), ddd (doublet of 
doublet of doublets), t (triplet), q (quartet), m (multiplet), and 
br (broad). Mass spectra (MS) were determined by MALDI 
instrument. 1 uL test compound solution in acetonitrile is 
mixed with an equal amount of the matrix Solution (saturated 
2,5-dihydroxybenzoic acid in 50% ethanol) on the MALDI 
plate. MALDI spectra were recorded in positive reflectron 
mode on an AXIMA curved-field reflectron (CFR) MALDI 
TOF mass spectrometer using a quadrupole ion-trap (QIT) 
MALDI-TOF instrument (Kratos/Shimadzu, Columbia, Md., 
USA). Analytical HPLC was performed using a C18 Phe 
nomenex quantitative 5 um 4.6 mmx 150 mm column with a 
30 minute gradient of solvent from 10% to 90% CHCN in 
HO. Retention time (R) was recorded in minutes and purity 













lated from 9% area under the peak (AEP). All final purified 
compounds showed purity levels greater than 95%. 
Example 1 
Preparation of 5-ethyl-2-(piperazin 
1-yl)pyrimidine (1) 
a) A mixture of tert-butyl piperazine-1-carboxylate (6.5 
gm, 35.2 mmol), 2-chloro-4-ethylpyrimidine (5 gm, 35.2 
mmol), triethylamine (3.55 gm, 35.2 mmol), and absolute 
ethanol (60 ml) were refluxed for 12 h and then cooled. Ice 
water was added and the resulting precipitate was filtered, 
washed with cold water, and finally dried to afford the desired 
crude intermediate, tert-butyl 4-(5-ethylpyrimidin-2-yl)pip 
erazine-1-carboxylate, as white flakes (9.24 gm, 90% yield); 
mp: 67-68° C. "H-NMR (DMSO-d6): 8 1.19 (t, J–7.56 Hz, 
3H), 1.46 (s.9H), 2.47 (q, J=7.56 Hz, 2H), 3.49 (t, J=4.8 Hz, 
4H), 3.76 (t, J=4.8 Hz, 4H), 8.19 (s. 2H). 'C-NMR (DMSO 
d6): 8 15.59, 22.66, 28.4, 43.76, 43.77, 79.8, 124.95, 154.84, 
157.08, 160.05. MS: calcd 292.19 for CHNO, MI". 
found, 293.19 M+1". b) HC1/MeOH mixture was prepared 
by adding 10 ml acetylchloride dropwise to 100 ml methanol 
at 0°C. The resulting mixture was warmed to room tempera 
ture. The intermediate from step a (9 gm, 30.8 mmol) was 
then added to the HC/MeOH and stirred for 12 h at room 
temperature. Methanol was removed using a row: evaporator. 
The residue was dissolved in water; the solution was neutral 
ized using solid NaHCO. The mixture was extracted with 
CHCl (3x200 mL). The combined organic layers was 
washed successively with saturated NaHCO, and saturated 
brine and then dried with anhydrous NaSO. Concentration 
of the organic layer afforded the desired crude product 1 as a 
white solid (4.8 gm, 81% yield); mp: 115-116° C. "H-NMR 
(DMSO-d6): 8 1.20 (t, J=7.56 Hz, 3H), 2.48 (q, J=7.56 Hz, 
2H), 3.09 (t, J=5.16 Hz, 4H), 3.94 (t, J=5.16 Hz, 4H), 8.19 (s. 
2H). 'C-NMR (DMSO-d6): & 15.53, 22.67, 42.76, 44.30, 
125.52, 157.15, 160.09. 
Example 2 
Preparation of 5-benzyl-2-(piperazin 
1-yl)pyrimidine (2) 
a) A mixture of KCO (6 gm, 43.5 mmol. 3 equiv) and 
Pd(PPh) (1 gm, 0.86 mmol) were stirred at room tempera 
ture in 20 mL THF/water (1:1) for 30 minutes. Tert-butyl 
4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (5 gm, 
14.5 mmol. 1 equiv) was then added with B-benzyl-9-BBN (2 
equiv. 49 ml of a 0.5 M solution in THF). The resulting 
mixture was heated with stirring under argon atmosphere in 
an oil bath adjusted at 100-110° C. until the reaction had 
reached completion, as monitored by TLC. The reaction mix 
ture was extracted with CHCl (3x200 mL). The combined 
organic layers were then dried with anhydrous NaSO. Chlo 
roform was evaporated under reduced pressure and the resi 
due was purified using flash column chromatography (ini 
tially with 4:1 hexane/ethyl acetate and finally with 1:1 
hexane/ethyl acetate). Tert-butyl 4-(5-benzylpyrimidin-2-yl) 
piperazine-1-carboxylate was obtained as a yellow solid (3.8 
gm, 74% yield); mp: 121-123° C. "H-NMR (DMSO-d6): 8 
1.47 (s.9H), 3.47 (t, J–4.68 Hz, 4H), 3.75 (t, J=4.68 Hz, 4H), 
3.78 (s. 2H), 7.14-7.29 (m, 5H), 8.16 (s. 2H). 'C-NMR 
(DMSO-d6): 8 28.4, 35.61, 43.70, 79.92, 122.29, 126.41, 
128.51, 128.66, 140.02, 154.84, 157.87, 160.69. MS: calcd 
354.21 for C20HNO, MI. found, 355.21 M+1. b)3.7 
gm of the obtained product from step a was then deprotected 
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using HCl/MeOH as described above in the preparation of 1. 
As a result, compound 2 was obtained as a pale yellow solid 
(2.2gm, 80% yield); mp: 108-110° C. "H-NMR (DMSO-d6): 
& 1.89 (s, 1H), 2.93 (t, J–4.8 Hz, 4H), 3.76 (t, J–4.8 Hz, 4H), 
3.79 (s. 2H), 7.17-729 (m, 5H), 8.18 (s. 2H). 'C-NMR 
(DMSO-d6): 8 35.59, 44.96, 45.92, 121.79, 126.34, 128.48, 
128.6, 140.1, 157.8, 160.5. MS: calcd 254.15 for C15HN 
M. found, 255.15 M+1. 
Example 3 
Preparation of 4-(4-(5-ethylpyrimidin-2-yl)piper 
azin-1-yl)guinazoline (3) 
A mixture of 1 (72 mg, 0.377 mmol), 4-chloroquinzoline 
(61 mg, 0.377 mmol), and triethylamine (38 mg, 0.377 mmol) 
in isopropanol (5 ml) was refluxed at 80°C. for 1.5 hr. The 
solid separated out of the reaction was filtered, washed with 
hot solvent and dried to afford compound 3 which was 
obtained as a yellow solid (61 mg, 50% yield); mp: >250° C. 
The purity of 3 was confirmed using HPLC (97.27%, 
R=9.987). 'H-NMR (DMSO-d6): 8 1.13 (t, J–7.56 Hz, 3H), 
2.45 (q, J=7.56 Hz, 2H), 3.95 (t, J=5.28 Hz, 4H), 4.16 (t, 
J=5.28 Hz, 4H), 7.68 (ddd, J=1.38 Hz, J=6.84 Hz, J=8.4 Hz, 
1H), 7.96 (m, 2H), 8.22 (d. J=8.4 Hz, 1H), 8.31 (s. 2H), 8.82 
(s, 1H). 'C-NMR (DMSO-d6): & 15.63, 21.91, 42.85, 48.78, 
113.28, 121.66, 125.04, 126.69, 126.88, 134.78, 143.5, 
149.89, 157.19, 159.95, 162.51. MS: calcd 320.17 for 
C18HN MI". found, 320.39 (MI". 
Example 4 
Preparation of 4-(4-(5-benzylpyrimidin-2-yl)piper 
azin-1-yl)guinazoline (4) 
Compound 4 was prepared from 2 (90 mg, 0.354 mmol) 
and 4-chloroquinzoline (58 mg, 0.354 mmol) following the 
general procedure for the preparation of 4. The product was a 
yellow solid (86 mg, 63%); mp: >250°C. The purity of 4 was 
confirmed using HPLC (97.59%, R=15.025). H-NMR 
(DMSO-d6): 83.8 (s. 2H), 3.96 (t, J=5.16 Hz, 4H), 4.26 (t, 
J=5.16 Hz, 4H), 7.17-7.3 (m, 5H), 7.71 (ddd, J=2.22 Hz, 
J=6.36 Hz, J=8.4 Hz, 1H), 8.01 (m, 2H), 8.25 (d. J=8.4 Hz, 
1H), 8.34 (s. 2H), 8.86 (s, 1H). 'C-NMR (DMSO-d6): 8 
34.51, 42.6, 48.69, 112.49, 119.73, 123.03, 126.11, 126.98, 
127.32, 128.32, 128.54, 135.36, 140.86, 140.96, 148.74, 
157.84, 159.77, 162.12. MS: calcd 382.19 for CHN 
M", found, 383.35 M+1". 
Example 5 
Preparation of 4-(4-(5-ethylpyrimidin-2-yl)piper 
azin-1-yl)-2-phenylduinazoline (5) 
Compound 5 was prepared from 1 (72 mg, 0.377 mmol) 
and 2-phenyl-4-chloroquinzoline (90 mg. 0.377 mmol) fol 
lowing the general procedure for the preparation of 3. The 
product was a white solid (100 mg, 67%); mp: 137-138°C. 
The purity of 5 was confirmed using HPLC (96.43%, 
R=1509). 'H-NMR (DMSO-d6): 8 1.14 (t, J–7.56 Hz, 3H), 
2.44 (q, J=7.56 Hz, 2H), 3.93-3.98 (m, 8H), 7.50-7.54 (m, 
4H), 7.83 (ddd, J=1.38 Hz, J=6.84 Hz, J=8.28 Hz, 1H), 7.9 
(dd, J=0.96 Hz, J=8.28 Hz, 1H), 8.1 (dd, J=0.96 Hz, J=8.28 
HZ, 1H), 8.3 (s. 2H), 8.51 (m, 2H). 'C-NMR (DMSO-d6): 8 
15.6, 21.93, 43.33, 48.85, 114.75, 119.3, 123.55, 125.36, 













157.13, 158.08, 160.36, 164.12. MS: calcd 396.21 for 
CHN MI". found, 397.4 M+1". 
Example 6 
Preparation of 4-(4-(5-benzylpyrimidin-2-yl)piper 
azin-1-yl)-2-phenylduinazoline (6) 
Compound 6 was prepared from 2 (90 mg, 0.354 mmol) 
and 2-phenyl-4-chloroquinzoline (84 mg. 0.354 mmol) fol 
lowing the general procedure for the preparation of 3. The 
product was a white solid (160 mg. 98%); mp: 135-137° C. 
The purity of 6 was confirmed using HPLC (98.57%, 
R=19.707). 'H-NMR (DMSO-d6): 83.79 (s. 2H), 3.91-3.96 
(m, 8H), 7.17-7.30 (m, 5H), 7.49-7.54 (m, 4H), 7.82 (ddd, 
J=0.78 Hz, J=6.6 Hz, J–7.92 Hz, 1H), 7.9 (d. J=8.28 Hz, 1H), 
8.08 (d. J=8.28 Hz, 1H), 8.32 (s.2H), 8.51 (m,2H). 'C-NMR 
(DMSO-d6): 8 34.56, 43.24, 48.81, 114.74, 122.82, 125.35, 
125.4, 126.11, 127.95, 128.35, 128.56, 130.32, 132.89, 
138.02, 140.9, 152.11, 157.81, 158.06, 160.26, 164.09. MS: 
calcd 458.22 for CHN MI". found, 458.28 MI". 
Examples 7-12 
General Preparation of 
quinazoline-4-ylaminobenzoic acid and 
quinazoline-4ylaminomethylbenzoic acid 
intermediates (7-12) 
Either 4-chloroquinzoline or 2-phenyl-4-chloroquinzoline 
was reacted with an equivalent amount of the corresponding 
aminobenzoic acid or aminomethylbenzoic acid derivative in 
the presence of an equivalent amount of triethylamine using 
anhydrous isopropanol as a solvent. The reaction was per 
formed under 80° C. until the starting materials were con 
sumed. The solid furnished out of the reaction, after solvent 
evaporation, was washed with hot water to remove triethy 
lamine HCl and used in the next step without further purifi 
cation or elucidation. 
Example 13 
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin 
1-yl)(3-(quinazolin-4-ylamino)phenyl)methanone 
(13) 
Intermediate 1 (72 mg, 0.377 mmol) was reacted with 
intermediate 7 (99 mg 0.377 mmol) in the presence of 
equivalent amounts of both EDC.HCl (72 mg 0.377 mmol) 
and TEA (38 mg 0.377 mmol) using 5 ml of CH2Cl as a 
solvent. The reaction mixture was stirred under room tem 
perature overnight. The solvent was evaporated under pres 
Sure and the title compound was purified using flash column 
chromatography (2.5% MeOH in CHCl). The product was 
a white solid (107 mg, 64%); mp: 146-147°C. The purity of 
13 was confirmed using HPLC (97.1%, R=11.075). 
'H-NMR (DMSO-d6): 8 1.12 (t, J=7.44 Hz, 3H), 2.43 (q. 
J=7.44 Hz, 2H), 3.35-3.79 (br, m, 8H), 7.2 (dd, J=1.2 Hz, 
J=7.74 Hz, 1H), 7.48 (t, J=7.92 Hz, 1H), 7.65 (ddd, J=1.38 
Hz, J=7.38 Hz, J=8.28 Hz, 1H), 7.8 (dd, J=1.2 Hz, J=7.38 Hz, 
1H), 7.87 (ddd, J=1.38 Hz, J=7.08 Hz, J=8.28 Hz, 1H), 7.98 
(ddd, J=0.72 Hz, J=1.8 Hz, J=8.28 Hz, 1H), 8.02 (t, J=1.68 
HZ, 1H), 8.27 (s. 2H), 8.57 (dd, J=0.72 Hz, J=7.74 Hz, 1H), 
8.63 (s, 1H), 9.93 (s, 1H). 'C-NMR (DMSO-d6): & 15.58, 
21.9, 41.49, 43.34, 43.87, 46.95, 115.16, 120.82, 122.17, 
122.97, 123.18, 125.01, 126.38, 127.85, 128.67, 133.13, 
US 8,609.672 B2 
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135.88, 139.23, 149.7, 154.36, 157.13, 157.67, 16024, 
169.02. MS: calcd 439.21 for CHNO IMI". found, 
439.12 Mt. 
Example 14 
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin 
1-yl)(4-(quinazolin-4-ylamino)phenyl)methanone 
(14) 
Compound 14 was prepared from intermediate 1 (72 mg, 
0.377 mmol) and intermediate 8 (99 mg, 0.377 mmol) fol 
lowing the same procedure utilized in the preparation of 13. 
The product obtained was a white solid (100 mg, 60%); mp: 
248-249° C. The purity of 14 was confirmed using HPLC 
(95%, R=10.753). "H-NMR (DMSO-d6): & 1.12 (t, J=7.56 
Hz, 3H), 2.43 (q, J–7.56 Hz, 2H), 3.33-3.84 (br, m, 8H), 7.5 
(d. J=8.64 Hz, 2H), 7.66 (ddd, J=1.38, HZ, J–7.2 Hz, J=8.28 
HZ, 1H), 7.82 (d. J=8.28 Hz, 1H), 7.88 (ddd, J=1.38 Hz, J=7.2 
HZ, J=8.28 Hz, 1H), 8.02 (d. J–8.64 Hz, 2H), 8.27 (s. 2H), 
8.59 (d. J=8.46 Hz, 1H), 8.66 (s, 1H), 9.93 (s, 1H). 'C-NMR 
(DMSO-d6): 8 15.53, 21.87, 41.55, 43.6, 46.95, 115.19, 
121.34, 122.99, 124.92, 126.37, 127.62, 127.78, 127.84, 
130.37, 133.12, 140.57, 149.72, 1542, 157.1, 157.55, 1602, 
169.08. MS: calcd 439.21 for C.H.N.O MI". found, 
439.16 Mt. 
Example 15 
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin 
1-yl)(4-((quinazolin-4-ylamino)methyl)phenyl) 
methanone (15) 
Compound 15 was prepared from intermediate 1 (77 mg, 
0.405 mmol) and intermediate 9 (113 mg, 0.405 mmol) fol 
lowing the general procedure used in the preparation of 13. 
The product obtained was a white solid (40 mg, 21%); mp: 
170-171° C. The purity of 15 was confirmed using HPLC 
(95.48%, R=11.288). 'H-NMR (DMSO-d6): 8 1.11 (t, 
J–7.56 Hz, 3H), 2.42 (q, J=7.56 Hz, 2H), 3.34-3.76 (br, m, 
8H), 4.84 (d. J=5.82 Hz, 2H), 7.4 (d. J=8.4 Hz, 2H), 7.44 (d. 
J=8.4 Hz, 2H), 7.54 (ddd, J=1.2 Hz, J=6.72 Hz, J=8.28 Hz, 
1H), 7.7 (dd, J=0.84 Hz, J-7.56 Hz, 1H), 7.78 (ddd, J=1.2 Hz, 
J=6.72 Hz, J–8.28 Hz, 1H), 8.26 (s. 2H), 8.31 (dd, J=0.84 Hz, 
J=7.56 Hz, 1H), 8.46 (s, 1H), 8.9 (t, J=5.82 Hz, 1H). C 
NMR (DMSO-d6): 8 15.58, 21.89, 43.25, 43.75, 46.92, 
114.88, 122.63, 124.97, 125.77, 127.09, 127.23, 127.57, 
132.67, 134.27, 141.11, 149.17, 155.05, 157.12, 159.37, 
160.18, 169.13. MS: calcd 453.23 for C.H.N.O MI". 
found, 453 M". 
Example 16 
Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin 
1-yl)(3-(quinazolin-4-ylamino)phenyl)methanone 
(16) 
Compound 16 was prepared from intermediate 2 (90 mg. 
0.354 mmol) and intermediate 7 (93 mg 0.354 mmol) fol 
lowing the same procedure utilized in the preparation of 13. 
The product obtained was a white solid (125 mg, 70%); mp: 
120-122°C. The purity of 16 was confirmed using HPLC 
(97.17%, R=15.488). 'H-NMR (DMSO-d6): 83.34-3.78 (br. 
m, 10H), 7.17-729 (m, 6H), 7.48 (t, J=7.92 Hz, 1H), 7.65 
(ddd, J=0.96 Hz, J=6.96 Hz, J=8.88 Hz, 1H), 7.8 (d. J=7.56 
HZ, 1H), 7.87 (im. 1H), 7.98 (m. 1H), 8.02 (s, 1H), 8.31 (s, 













'C-NMR (DMSO-d6): 8 34.53, 41.5, 43.25, 43.78, 46.9, 
115.15, 120.82, 122.17, 122.96, 123.18, 126.12, 126.38, 
127.86, 128.34, 128.56, 128.67, 133.13, 139.23, 140.87, 
149.7, 154.36, 157.67, 157.81, 160.17, 169.02. MS: calcd 
501.23 for C30H.N.O.M. found, 501.95 |M|. 
Example 17 
Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin 
1-yl)(4-(quinazolin-4-ylamino)phenyl)methanone 
(17) 
Compound 17 was prepared from intermediate 2 (90 mg. 
0.354 mmol) and intermediate 8 (93 mg 0.354 mmol) fol 
lowing the procedure used in the preparation of compound 
13. The product obtained was a white solid (135 mg, 76%); 
mp: 245-247°C. The purity of 17 was confirmed using HPLC 
(96.73%, R=14.952). 'H-NMR (DMSO-d6): 83.05-3.8 (br. 
m, 10H), 7.18-7.31 (m, 5H), 7.5 (d. J=8.64 Hz, 2H), 7.67 
(ddd, J=1.38, HZ, J–7.2 Hz, J=8.1 Hz, 1H), 7.82 (d. J=8.28 
HZ, 1H), 7.89 (ddd, J=1.2 Hz, J=6.96 Hz, J=8.28 Hz, 1H), 
8.04 (d. J=8.64 Hz, 2H), 8.32 (s. 2H), 8.65 (d. J=8.1 Hz, 1H), 
8.67 (s, 1H), 10.01 (s, 1H). 'C-NMR (DMSO-d6): 8 34.50, 
43.52, 45.38, 115.20, 121.73, 122.87, 123.11, 126.08, 
126.35, 127.75, 127.8, 128.3, 128.51, 130.34, 133.12, 
140.59, 140.83, 149.69, 154.27, 157.57, 157.78, 160.13, 
169.09. MS: calcd 501.23 for C30H NO IMI". found, 
501.74 M. 
Example 18 
Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin 
1-yl)(4-((quinazolin-4-ylamino)methyl)phenyl) 
methanone (18) 
Compound 18 was prepared from intermediate 2 (102 mg, 
0.405 mmol) and intermediate 9 (113 mg, 0.405 mmol) fol 
lowing the general procedure used in the preparation of 13. 
The product obtained was a white solid (40 mg, 19%); mp: 
99-101° C. The purity of 18 was confirmed using HPLC 
(96.14%, R=15.95). "H-NMR (DMSO-d6): 83.37-3.83 (br. 
m, 10H), 4.89 (d. J=5.82 Hz, 2H), 7.22-7.34 (m, 5H), 7.43 (d. 
J=8.28 Hz, 2H), 7.49 (d. J=8.28 Hz, 2H), 7.6 (ddd, J=1.2 Hz, 
J=6.72 Hz, J=8.28 Hz, 1H), 7.76 (dd, J=0.84 Hz, J-7.56 Hz, 
1H), 7.84 (ddd, J=1.2 Hz, J=6.72 Hz, J=8.28 Hz, 1H), 8.34 (s, 
2H), 8.36 (d. J=7.92 Hz, 1H), 8.51 (s, 1H), 8.94 (t, J=5.82 Hz, 
1H). 'C-NMR (DMSO-d6): 8 34.49, 43.23, 114.86, 122.61, 
122.89, 125.74, 126.09, 127.07, 127.2, 127.54, 128.31, 
128.53, 132.62, 134.23, 140.83, 141.09, 149.17, 155.02, 
157.77, 159.36, 160.1, 169.1. MS: calcd 515.24 for 
C31H NO IMI". found, 515 MI". 
Example 19 
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin 
1-yl)(2-(3-phenylduinazolin-4-ylamino)phenyl) 
methanone (19) 
Compound 19 was prepared from intermediate 1 (120 mg. 
0.625 mmol) and intermediate 10 (213 mg 0.625 mmol) 
following the same procedure utilized in the preparation of 
13. The product obtained was a white solid (210 mg, 40%); 
mp: 204-205°C. The purity of 19 was confirmed using HPLC 
(97.67%, R=15.123). "H-NMR (DMSO-d6): 8 1.09 (t, 3H), 
2.4 (q, 2H), 3.16-3.71 (m, 8H), 7.18 (d. J–7.56 Hz, 1H), 
7.41-7.59 (m, 5H), 7.83 (m, 2H), 8.02 (m, 1H), 8.13 (m, 1H), 
8.21 (s. 2H), 8.4 (m, 2H), 8.54 (d. J=8.22 Hz, 1H), 9.87 (s, 
US 8,609.672 B2 
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1H). 'C-NMR (DMSO-d6): 8 15.36, 21.85, 42.66, 44.25, 
114.01, 120.67, 121.79, 122.86, 125.02, 125.97, 127.9, 
128.16, 128.27, 128.6, 130.12, 130.2, 133.23, 136.23, 138.3, 
139.59, 150.56, 157.03, 157.92, 159.02, 160.3, 169.2. MS: 
calcd 515.24 for C31HNOMI". found, 515.84 |M|.. 5 
Example 20 




Compound 20 was prepared from intermediate 1 (120 mg. 
0.625 mmol) and intermediate 11 (213 mg 0.625 mmol) 
following the same procedure utilized in the preparation of 
13. The product obtained was a white solid (180 mg, 34%); 
mp: >250° C. The purity of 20 was confirmed using HPLC 
(96.02%, R=14.823). "H-NMR (DMSO-d6): 8 1.12 (t, 3H), 
2.43 (q, 2H), 3.32-3.78 (m, 8H), 7.51-7.65 (m, 6H), 7.89 (m, 
2H), 8.12 (m, 2H), 8.27 (s. 2H), 8.47 (m, 2H), 8.6 (d. J=8.28 
HZ, 1H), 10.0 (s, 1H). 'C-NMR (DMSO-d6): 8 15.54, 21.88, 
43.59, 114.04, 121.22, 123.07, 124.92, 126.07, 127.91 
128.17, 128.47, 130.28, 130.33, 133.36, 138.16, 140.74, 
150.53, 157.1, 157.77, 158.94, 160.22, 169.11. MS: calcd 




Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin- 30 
1-yl)(4-((2-phenylduinazolin-4ylamino)methyl)phe 
nyl)methanone (21) 
Compound 21 was prepared from intermediate 1 (120 mg. 
0.625 mmol) and intermediate 12 (221 mg 0.625 mmol) 
following the same procedure utilized in the preparation of 
13. The product obtained was a white solid (105 mg, 20%); 
mp: 207-208°C. The purity of 21 was confirmed using HPLC 
(97.08%, R=15.735). H-NMR (DMSO-d6): & 1.1 (t, 3H), 
2.41 (q, 2H), 3.34-3.76 (m, 8H), 4.97 (d. J=5.82 Hz, 2H), 
7.4-7.55 (m, 8H), 7.79 (m, 2H), 8.25 (s. 2H), 8.33 (m. 1H), 
8.43 (m, 2H), 8.98 (t, J=5.82 Hz, 1H). 'C-NMR (DMSO 
d6): 815.56, 21.88,414, 43.26, 43.56, 46.85, 113.79, 122.68, 
124.94, 125.45, 127.24, 127.31, 127.84, 128.2, 130.3, 
132.83, 134.26, 138.52, 141.51, 149.98, 157.1, 159.15, 
159.59, 160.16, 169.11. MS: calcd 529.26 for C32HNO 






Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin 
1-yl)(3-(2-phenylguinazolin-4ylamino)phenyl) 
methanone (22) 
Compound 22 was prepared from intermediate 2 (120 mg, 55 
0.472 mmol) and intermediate 10 (160 mg. 0.472 mmol) 
following the same procedure utilized in the preparation of 
13. The product obtained was a white solid (135 mg, 23%); 
mp: 214-215°C. The purity of 22 was confirmed using HPLC 
(95.38%, R=18.948). 'H-NMR (DMSO-d6): 83.37-3.83 (br. 
m, 10H), 7.2-7.32 (m, 6H), 7.44-7.67 (m, 5H), 7.91 (m, 2H), 
8.1 (ddd, J=0.9 Hz, J=2.1 Hz, J=8.28 Hz, 1H), 8.2 (m. 1H), 
8.32 (s. 2H), 8.47 (m, 2H), 8.62 (d. J=8.28 Hz, 1H), 10.0 (s, 
1H). 'C-NMR (DMSO-d6): 8 34.53, 41.46, 43.84, 46.95, 
113.99, 120.65, 121.84, 122.89, 122.98, 123.02, 126.07, 
126.11, 127.88, 128.17, 128.33, 128.54, 128.66, 128.78, 




140.85, 150.49, 157.77, 157.85, 158.92, 160.15, 169.14. MS: 
calcd 577.26 for C36H, NOMI". found, 577.55 Mt. 
Example 23 
Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin 
1-yl)(4-(2-phenylquinazolin-4ylamino)phenyl) 
methanone (23) 
Compound 23 was prepared from intermediate 2 (120 mg. 
0.472 mmol) and intermediate 11 (160 mg. 0.472 mmol) 
following the same procedure utilized in the preparation of 
13. The productobtained was a white solid (70 mg, 12%); mp: 
>250° C. The purity of 23 was confirmed using HPLC (95%, 
R=18.98). 'H-NMR (DMSO-d6): 83.38-3.82 (br, m, 10H), 
7.21-7.33 (m, 6H), 7.53-7.69 (m, 5H), 7.93 (m, 2H), 8.15 (m. 
2H), 8.34 (s. 2H), 8.51 (m, 2H), 8.64 (d. J=8.28 Hz, 1H), 
10.06 (s, 1H). 'C-NMR (DMSO-d6): 83456, 43.53, 11408, 
121.28, 122.95, 123.11, 126.16, 127.98, 128.21, 128.38, 
128.54, 128.6, 128.75, 130.29, 130.42, 131.47, 133.44, 
138.19, 140.8, 140.89, 150.57, 157.83, 159, 160.18, 169.19. 
MS: calcd 577.26 for CHNOMI. found, 577.69 Mt. 
Example 24 
Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin 
1-yl)(4-((2-phenylduinazolin-4-ylamino)methyl) 
phenyl)methanone (24) 
Compound 24 was prepared from intermediate 2 (120 mg, 
0.472 mmol) and intermediate 12 (167 mg, 0.472 mmol) 
following the same procedure utilized in the preparation of 
13. The productobtained was a white solid (59 mg, 10%); mp: 
216-217° C. The purity of 24 was confirmed using HPLC 
(97.27%, R=19.543). H-NMR (DMSO-d6): & 3.37-3.79 
(br, m, 10H), 4.99 (d. J=5.82 Hz, 2H), 7.19-7.31 (m, 5H), 
742-7.66 (m, 8H), 7.82 (m, 2H), 8.3 (s. 2H), 8.35 (d. J=8.22 
HZ, 1H), 8.44-8.47 (m, 2H), 9.02 (t, J=5.82 Hz, 1H). C 
NMR (DMSO-d6): 8 34.51, 43.24, 43.56, 113.79, 122.68, 
122.88, 125.45, 126.1, 127.23, 127.3, 127.84, 128.2, 128.31, 
128.53, 130.04, 132.83, 134.24, 138.52, 140.83, 141.51, 
149.98, 157.77, 159.15, 159.58, 160.09, 169.12. MS: calcd 
591.27 for CHNOMI". found, 591.69 |M|. 
Example 25 
Preparation of 4-(4-(5-bromopyrimidin-2-yl)piper 
azin-1-yl)-6-fluoroquinazoline (25) 
A mixture of 5-bromo-2-(piperazin-1-yl)pyrimidine (240 
mg, 1.0 mmol), 4-chloro-6-fluoroquinzoline (180 mg, 1.0 
mmol), and diisopropylethylamine (190 mg, 1.5 mmol) in 
isopropanol (10 ml) was refluxed at 80° C. for 1.5 hr. The 
Solid separated out of the reaction upon cooling and was 
filtered, washed with hot solvent and dried to afford com 
pound 25 which was obtained as fine white crystals (317 mg, 
81% yield). H-NMR (DMSO-d6): 83.8 (m, 4H), 3.9 (m, 
4H), 7.75 (m, 2H), 7.88 (dd. 1H), 8.48 (s. 2H), 8.62 (s, 1H). 
'C-NMR (DMSO-d6): 843.7, 49.0, 106.25, 109.95, 110.15, 
116.9, 117.0, 122.95, 123.15, 148.95, 153.75, 158.2, 158.5, 
159.85, 159.95, 163.95. 
Example 26 
Preparation of (4-(5-bromopyrimidin-2-yl)piperazin 
1-yl)(4-(6-fluoroquinazolin-4-ylamino)methyl)phe 
nyl)methanone (26) 
Compound 26 was prepared from 4-chloro-6-fluoroquin 
Zoline (11 mg, 0.06 mmol), following the same procedure 
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utilized in the preparation of 13. The product 26 obtained was 
a pale yellow solid (19 mg, 60%). "H-NMR (DMSO-d6): 8 
3.33-3.84 (brm,8H), 4.84 (d. J=6.6 Hz, 2H), 7.37 (d. J=9 Hz, 
2H), 7.41 (d. J=9 Hz, 2H), 7.68 (ddd, J=3 Hz, J=8.4 Hz, J=9 
HZ, 1H), 7.76 (dd, J=6.6 Hz, J=9 HZ, 1H), 8.14 (dd, J=3.6 Hz, 
J=9 HZ, 1H), 8.34 (s, 1H), 8.35 (s, 1H), 8.43 (s, 1H), 8.81 (t, 
J=6 Hz, 1H). 
Biological Methods 
Growth Inhibition of NCI-60 Tumor Cell Lines 
The NCI-DTP uses the SRB (sulforhodamine B) assay to 
measure the ability of a test compound to inhibit the growth of 
a given cell line. The cell lines used in the NCI-60 are main 
tained using RPMI 1640 medium supplemented with 5% fetal 
bovine serum and 2 mM L-glutamine. Cell lines are seeded 
into a series of 96-well microtiter plates, with varied inocu 
lation densities, depending on the growth rate and doubling 
time of each cell line. The plates are then incubated at 37°C., 
5% CO, 95% air and 100% relative humidity for 24 hours 
before treating with the test compounds. On the treatment 
day, experimental agents are added to the cells with a series of 
target final concentrations: 100, 10, 1, 0.1, and 0.01 uM. After 
48 hours treatment while being incubated under the above 
conditions, the cells are fixed with trichloroacetic acid (con 
centration differs according to the nature of the cell line: 
adherent or suspension) for one hour at 4°C. After removal of 
the Supernatant, the plates are washed with water several 
times and dried completely in the air. Then 100 uL of 0.4% 
sulforhodamine B (SRB) solution in 1% acetic acid is added 
for 10 minutes. The unbound dye is removed and the plates 
are washed with 1% acetic acid. The bound dye is then solu 
bilized with 10 mM trizma base, and the absorbance is mea 
sured using a plate reader at 515 nm. The same treatment and 
measurement were performed for cells prior to treatment and 
were assigned TZ (T-zero). The % growth was calculated 
using the following equation: 
(T-T)x100 % growth = 
gr (C-T) 
where Ti is the reading for the treated well after two days of 
the treatment with a certain concentration of a specific com 
pound. C is the average reading measured in the untreated 
wells after two days of treatment with the vehicle. TZ is the 
average reading measured prior to treatment. GI50 is the dose 
that causes 50% inhibition of the growth after the treatment 
time compared to the TZ and calculated from 
(T-T)x100 
% growth = 50 = (C-T) 
TGI is the dose that causes a total inhibition of the growth and 
can be computed using the equation: Ti-TZ. LC50 is the dose 
that kills 50% of the cells compared to the cell density at the 
treatment time and calculated from 
(T-T)x100 
T. 
MTT Viability Assay 
MDA-MB-468 human breast cells were obtained from 
ATCC and cultured in RPMI 1640 medium (ATCC) supple 
mented with 10% FBS (Invitrogen), and 2% antibiotic-anti 
mycotic mixture of Penicillin-G, Streptomycin sulfate, and 
Amphotericin B (Invitrogen) in a 5% CO-95% humidity 
incubator at 37° C. 3-4,5-dimethylthiazol-2-yl)-2,5-diphe 
nyltetrazoliumbromide (MTT) assay was chosen to deter 
mine the IC50 (the concentration required to inhibit survival 














MDA-MB-468 cell line using gefitinib as a positive control. 
5000 cells, in 100 uL of the culture medium, were plated per 
well in 96-well plates. Cells were allowed to adhere for 1 day. 
Cells were then treated with fresh culture medium containing 
one of several concentrations of the test compounds; 100, 10. 
1, 0.1, 0.01, 0.001 uM. The plates were processed after 48,72, 
or 120 hours via discarding the media and adding 100 uI, 0.5 
mg/ml MTT reagent in fresh culture media. The plates were 
then incubated for 4 hours under 10% CO2 at 37° C. The 
media was then removed and 100 uL of DMSO was added to 
each well to dissolve the formed formazone crystals. Plates 
were kept at room temperature over night away from light. 
The optical density of the formed violet color was quantified 
using an automatic spectrophotometer (Tristar LB 941) at a 
wavelength of 562 nm. The experiment was carried out with 
triplicate for each concentration of a given compound. Three 
independent experiments were conducted at three different 
dates. The concentration required for 50% reduction in the 
optical density, and hence the viability compared to control 
vehicle treated wells, was estimated for each compound 
against the studied cell line by non-linear regression analysis 
of the Log 10 concentration in moles versus % viability 
curves. Curve fitting was performed using the variable slope 
four parameter module implemented in the GraphPad Prism 
software (version 5.02). 
Kinase Binding Screening 
Biotinylated kinase ligand was immobilized onto Strepta 
vidin coated magnetic beads and washed with blocking 
buffer. The liganded beads were then incubated with DNA 
tagged kinase in the presence of test compound for 1 hat room 
temperature. Binding reactions were carried out in 20% 
Seablock, 0.17xPBS, 0.005% Tween 20, 6 mMDTT, in a final 
Volume of 0.04 mL. Beads were then washed with wash 
buffer (PBS, 0.05% Tween 20), and then incubated with elu 
tion buffer (PBS, 0.05% Tween 20, 0.5 M non-biotinylated 
kinase ligand) and eluted. The kinase concentration in the 
eluate was then measured by quantitative PCR. The detected 
signal is proportional to the number of eluted DNA-tagged 
kinase molecules and hence to the binding potency of a given 
test compound. The results of this single dose screening are 
reported in the form of binding percentage of control 
(B-POC) which is defined as follows: 
test compound signal-positive control signal) x 100 B-Poc=1 p gnal-p gnal) x 100 
(negative control signal-positive control signal) 
The negative control signal is obtained by the vehicle and 
corresponds to B-POC=100%. The positive signal control is 
detected by a binding positive compound and is B-POC 0%. 
The B-POC results are the average of duplicate measure 
ments. Only interactions with B-POC-35 were considered 
significant and thus used for calculating the selectivity Scores 
(Table 1) of the test compounds as follows: 
number of kinases showed B-POCs 35 
S(35) = -- - - 
(35) total number of wild-type kinases(198) 
In order to determine the Kd, the above procedure is followed 
at 11-point three fold serial dilution of the test compound, 
from 30 M to 0.508 nM, with the result of a standard dose 
response curve. The Kid is then calculated according to the 
following equation: 
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signal-background 
response = background+ . . . . . . 
1 + K P + dosehill slope 
hill slope=-1. A non-linear least square fit with the Leven 
berg-Marquardt algorithm was implemented to fit the curves 
(FIG. 3). Kinase binding assays were performed by Ambit 
Bioscience (San Diego, Calif., USA). 
The results of kinase binding assay are shown in Table 1, 
5 
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In Vitro Cellular Screening 
Compounds 3-6 and 13-24 were screened in-house against 
A549 (NSCLC) and MCF7 (breast cancer) cell lines to test 
the target compounds cytotoxic potential and to reduce the 
number of compounds to be further investigated (data not 
shown). The structures of the active compounds were submit 
ted for screening against the NCI-60 cell lines panel. Com 
pounds (3-4, 13, 15-16, and 19-23) were initially accepted for 
screening against the NCI-60 at a single concentration of 10 
which includes the B-POC values of 10M of compounds 4, 10 uM. Eight out of the above compounds (3-4, 13, 15-16, and 
15, and 16 against the most sensitive kinases tested within this 19-21) showed significantantiproliferative activity at a 10uM 
binding experiment. Kinases are ranked according to their dose and were accordingly evaluated at five concentrations in 
sensitivity towards binding by each compound separately order to determine their dose-response behavior and calculate 
from the most (lower B-POC) to the least (higher B-POC) their GI50 (dose inhibiting 50% of the growth compared to 
sensitive. Kinases within the same subfamily are highlighted. 15 the control), TGI (dose inhibiting the growth completely), 
Selectivity scores (S35) of the test compounds against a total and LC50 (dose killing 50% of the starting cell population) 
of 198 wild-type non-mutant kinases. K values of 4 against values. Table 2 shows the GI50, TGI, and LC50 values for 
selected PDGFR subfamily members are in parentheses and compounds 4, 15, and 16. Three compounds (3-4 and 15) 
expressed in uM. Both the B-POC and K values are the showed an interesting pattern of cytotoxic activity and were 
average of duplicate measurements. submitted for retesting in order to confirm the reproducibility 
TABLE 1 
B-POC (K) 
Kinase 4 Kinase 15 Kinase 19 - 
CEOK O ABL1(F317L)- 6.8 RIPK1 19 
phosphorylated 
0.5 (0.11) BRAFV600E 13 ABL1(F317L)- 20 
3.4 


































Number of kinases with B-POC is 35 15 7 
S(35) O.075 
Functional Kinase Inhibition Assay 
This experiment was conducted by mixing the test kinase, 
10 uM Y-33P-ATP, positively charged substrate, magnesium 
acetate, 1 uM test compound, and reaction buffer at room 
temperature. The reaction is then stopped by the addition of 
phosphoric acid solution. 10 uL of the reaction is filtered 
through a P30 filament, washed properly, dried, and finally 
Subjected to Scintillation counting. The inhibition of a given 
kinase is represented by the function percentage of control 
(F-POC) which is calculated as follows: 
mean(counts - blanks). X 100 
F-POC = 
mean(counts - blanks) 
test
negative control 
The assay was performed in duplicates. Dose-response 
curves were fitted using nonlinear regression as implemented 
in GraphPad Prism software (version 5.02). A Sigmoidal 
dose-response (variable slope) was used in this case (FIG. 4). 






of their cellular actions. The three compounds gave reproduc 
ible results, and compound 15 was chosen Subsequently by 
the DTP-BEC (Developmental Therapeutic Program-Bio 
logical Evaluation Committee) to advance to the MTD 
(Maximum Tolerated Dose) testing in vivo. According to the 
NCI-anticancer Screening paradigm, if 15 is safe in healthy in 
vivo models, it will be further subjected to the in vivo hollow 
fiber assay, and possibly human tumor Xenografts in an 
attempt to measure its in vivo anticancer potential (Shoe 
maker, R. H. Nature Reviews Cancer 2006, 6, 813-823; Ske 
han, P. et al. Journal of the National Cancer Institute 1990, 
82, 1107-1112: Takimoto, C. H. Cancer Chemotherapy and 
Pharmacology, Supplement 2003, 52). 
The GI50 (dose inhibiting 50% of the growth compared to 
control), TGI (dose inhibiting the growth completely), and 
LC50 (Dose killing 50% of the starting number of cells) 
values result from screening of compounds 4, 15, and 16 
against the NCI-60 cell line panel after 48 hours treatment are 
shown in Table 2. All values are given in LM. Cells high 
lighted in bold have values: 0.1<GI50s1 uM. 
  





GIso TGI LCso GIso TGI 
BT-549 1.26 18.40 43.OO 0.34 10.70 
T-47D 0.71 45.5O >100 1.25 >100 
MDA-MEB-468 0.06 2.73 >100 0.03 2.22 
Mean 5.24 37.15 81.28 4.46 S128 
Compound 16 (NSC: D-750776) shows the highest overall 
potency and non-selectivity against the cell lines and it does 
not display a significant difference between its cytostatic 
markers (mean GI50=1.05uM and mean TGI-3.24 uM) and 
cytotoxic indicator (LC50=22.91 uM). These data could be 
projected into potential toxicity against normal cells resulting 
in a narrow therapeutic index. On the other hand, 4 (NSC: 
D-750901) and 15 (NSC: D-750905) display a pattern of 
selective cytostatic potency against certain cell lines scattered 
among different tissues of origin. For example, 15 is potent 
against RPMI-8226 (leukemia, G150–68 nM), NCI-H23 
(lung, GI50–90 nM), SK-MEL-5 (skin, GI50–61 nM), and 
MDA-MB-468 (breast, GI50–30 nM) cancer cell lines. These 
two derivatives, 4 and 15, also show a significant difference 
between their cytostatic markers (mean GI50 & mean TGI) 
and cytotoxic indicator (mean LC50). These data may clas 
Sify 4 and 15 as cytostatic compounds whereas 16 may be 
described as a cytotoxic agent. According to the data pre 
sented in Table 2, and the testing reports obtained from the 
NCI-60 screening, the relationships between the structure 
variations of the piperazinylpyrimidine derivatives and their 
cytostatic/cytotoxic activities can be summarized as shown in 
FIG. 5. A benzyl group in the 5-position of pyrimidine ring 
may lead to more antiproliferative activity compared to ethyl 
substitution. Derivatives based on 2-phenylquinazoline based 
derivatives show overall weaker antiproliferative potential 
compared to the quinazoline based derivatives. Concerning 
the linkers in group II compounds, the para orientation shows 
the least cytotoxic activity whereas the metapositioning leads 
to the most potent derivatives (e.g., compound 16). Incorpo 
ration of a flexibility inducing element may have refined the 
series into the selective cytostatic performance of 15. Without 
being bound by any theory, the correlation between the cel 
lular profile of 4 (group I) and 15 (group II) in both terms of 
cellular selectivity and cytostatic rather than cytotoxic action 
raises the hypothesis that they both can affect similar set of 
targets in the cell and that 15, through its flexible methylene 
group, is able to attain a conformational ensemble very simi 
lar to those attained by the more rigid derivative, 4, devoid of 
any linkers. 
The concentration and time dependencies of the antipro 
liferative activity of compounds 4, 15, and 16 against MDA 
MB-468 cell line were further investigated using MTT assay. 
This cell line represents the triple negative/basal like breast 
carcinoma which is usually accompanied by frequent 
relapses and poor survival, reflecting the need for efficient yet 
safe agents to be used in this specific clinical setting. The 
MDA-MB-468 cell line is also sensitive to DNA-damaging 
agents which are known to be highly toxic and non-selective 
(Oliveras-Ferraros, C. et al. International Journal of Oncol 
ogy 2008, 33, 1165-1176). MDA-MB-468 cell line is known 
to overexpress EGFR receptor (Nautiyal, J. et al. Molecular 
Cancer Therapeutics 9, 1503-1514.). Therefore, gefitinib, 












LCso GIso TGI LCso 
>100 0.44 174 5.37 
>100 0.24 7.59 S.62 
>100 0.74 3.47 -100 
>100 105 3.24 22.91 
positive control. According to the dose-response curves 
shown in FIG. 6, the antiproliferative activity of a given test 
compound is directly proportional to the treatment time and 
the concentration. The ranking of activity according to the 
obtained IC50 values is as follows: 4 and 15 are more anti 
proliferative than 16 than gefitinib. 
Kinase Profiling of 4, 15, and 16 
The compounds of the present invention were structurally 
designed with the intention to interfere with certain members 
of the humankinome. Compounds 4, 15, and 16 were selected 
because they represent the three major structural variations 
and also because they were either selective cytostatic or 
potent cytotoxic on the cellular level. Compound 4 represents 
the direct attachment of the quinazoline ring with the piper 
azinylpyrimidine Scaffold (group I). Compound 15 exempli 
fies the use of a flexible linker whereas compound 16 has a 
more rigid incorporated linker and both belong to group II 
(FIG. 1). Two different kinase experiments were chosen for 
the current study. One is classified as a binding or non-bio 
chemical testing while the other is functional and biochemi 
cally oriented. 
In order to test the potential of 4, 15, and 16 to bind with the 
humankinome to which they were designed to target, a kinase 
binding assay was used to examine the ability of 10 uM of 4. 
15, or 16 to interfere with the binding of a given kinase with 
an immobilized, ATP directed agent (Karaman, M. W. et al. 
Nature Biotechnology 2008, 26, 127-132; Fabian, M.A. et al. 
Nature Biotechnology 2005, 23, 329-336; Pettus, L. H. et al. 
Journal of Medicinal Chemistry 2010, 53,2973–2985; Ander 
sen, C. B. et al. ACS Chemical Biology 2008, 3, 180-192: 
Jiang, J. K. et al. Journal of Medicinal Chemistry 2008, 51, 
8012-8018: Burns, C. J. et al. Bioorganic and Medicinal 
Chemistry Letters 2009, 19, 1206-1209; Chao, Q, et al. Jour 
nal of Medicinal Chemistry 2009, 52, 7808-7816.). A single 
dose of 10 uM was chosen to allow for detecting kinases able 
to bind to the test compounds. In this binding assay, a set of 
243 kinases were included. This set of kinases coversi) wild 
type Versus mutant kinases; and ii) phosphorylated versus 
non-phosphorylated set of either wild-type or mutant ABL1 
kinases (Table 3). Table 4 lists the kinases tested. A given 
interaction is represented by a numerical value called binding 
percentage of control (B-POC). The lower the B-POC value, 
the stronger the test compound binds with the test kinase. 
Only results with B-POCs50 are shown in Table 1 and are 
highlighted based on the kinases subfamilies, which aids in 
detecting the selectivity of the test compounds for being 
prototype inhibitors of certain kinase subfamilies. The 
kinases are ranked from the most to the least sensitive kinase 
towards binding with a given test compound. Table 1 illus 
trates that within the set of tested kinases, certain members of 
CDK, CK1, PDGFR, DDR, ABL, p38, RAF, or RIPK sub 
families are more or less recognized by the three test com 
pounds. Some members of CK1 subfamily are commonly 
recognized by the three test compounds. Compound 15 shows 
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almost equal affinity to bind to several members of CK1 
subfamily whereas CSNK1D is almost equivalently sensitive 
to the three derivatives: B-POC-26 against 4, B-POC–23 
against 15, and B-POC-22 against 16. Another CKI member, 
CSNKIE, is found to be sensitive towards 15 and 16 more 
than towards 4. CSNKIE is found to be significantly 
expressed in several cancer types compared to their normal 
tissues (Yang, W. S.; Stockwell, B. R. Genome Biology 
2008). Without being bound by any theory, the above results 
suggest that for CK1 subfamily members, the combination of 10 
piperazinylpyrimidine scaffold with quinazoline ring may be 
46 
tionally, compound 15 binds with higher affinity to BRAF and 
its common V600E mutant whereas 4 and 16 are recognized 
by RIPKI, another TKL (tyrosine kinase like) kinase. Among 
the tested unphosphorylated and phosphorylated derivatives 




- 0 Wild-type 1 198 
relevant for binding irrespective to the presence of linkers or Mutants 8 36 
a specific linker. Accordingly, CK1 family kinases, especially 
CSNK1D, may contain a common binding site which is able 
TABLE 4 
Description Kinases 
Wild-type Phosphorylated ABL1-phosphorylated 
Non-phosphorylated ABL1, ABL2, ACVR1, ACVR1B, ACVR2A, ACVR2B, 
Mutants 
ACVRL1, ADCK3, ADCK4, AKT1, AKT2, AKT3, ALK, 
AURKA, AURKB, AURKC, AXL, BLK, BMPR1A, 
BMPR1B, BMPR2, BMX, BRAF, BRK, BTK, CAMK2B, 
CDC2L1, CDC2L2, CDC2L5, CDK11, CDK2, CDK3, CDK4 
cyclinD1, CDK4-cyclinD3, CDK5, CDK7, CDK8, CDK9, 
CDKL1, CDKL2, CDKL3, CDKL5, CHEK1, CHEK2, CLK3, 
CSF1R, CSK, CSNK1A1, CSNK1A1 L, CSNK1D, CSNK1E, 
CSNK1G1, CSNK1G2, CSNK1G3, CSNK2A1, CSNK2A2, 
CTK, DAPK1, DAPK2, DAPK3, DCAMKL1, DDR1, DDR2, 
DYRK1B, EGFR, EPHA2, EPHA3, EPHA6, EPHA8, EPHB2, 
EPHB3, EPHB4, ERK1, FAK, FER, FES, FGFR1, FGFR2, 
FGFR3, FGFR4, FGR, FLT1, FLT3, FLT4, FRK, FYN, 
GSK3A, GSK3B, HCK, IGF1R, IKK-alpha, IKK-beta, IKK 
epsilon, INSR, INSRR, ITK, JAK1(JH1domain-catalytic), 
JAK2(JH1 domain-catalytic), JAK3(JH1domain-catalytic), 
JNK1, JNK2, JNK3, KIT, LCK, LKB1, LTK, LYN, MAP3K1, 
MAP3K15, MAP3K2, MAP3K3, MAP3K4, MAP4K2, 
MAP4K3, MAP4K4, MAP4K5, MAPKAPK2, MARK3, 
MEK1, MEK2, MERTK, MET, MKNK1, MKNK2, MLK1, 
MST1R, MTOR, MUSK, NEK1, p38-alpha, p38-beta, p38 
delta, p38-gamma, PAK1, PAK2, PAK3, PAK4, PAK6, PAK7, 
PCTK1, PDGFRA, PDGFRB, PDPK1, PIK3C2B, PIK3CA, 
PIK3CG, PIM1, PIM2, PIM3, PKAC-alpha, PLK1, PLK2, 
PLK3, PLK4, PRKCE, PRP4, PYK2, RAF1, RET, RIOK1, 
RIOK2, RIOK3, RIPK1, RIPK2, RIPK4, ROCK2, ROS1, 
RSK2(Kin. Dom.1-N-terminal), SNARK, SRC, SRMS, SRPK3, 
STK39, SYK, TAK1, TEC, TGFBR1, TGFBR2, TIE1, TIE2, 
TNIK, TNK1, TNK2, TNNI3K, TRKA, TRKB, TRKC, 
TSSK1B, TXK, TYK2(JH1domain-catalytic), TYRO3, ULK2, 
VEGFR2, VRK2, WEE1,YANK3, YES, ZAP70 
Phosphorylated ABL1(E255K)-phosphorylated, ABL1 (F317I)-phosphorylated, 
ABL1 (F317L)-phosphorylated, ABL1(H396P)-phosphorylated, 
ABL1(M351T)-phosphorylated, ABL1 (T315I)-phosphorylated, 
ABL1(Y253F)-phosphorylated, ABL1(Q252H)-phosphorylated, 
Non-phosphorylated ABL1 (F317I), ABL1 (F317L), ABL1(H396P), ABL1(Q252H), 
to accommodate piperazinylpyrimidine derivatives of differ 
ent molecular sizes and linkers. 
Compound 4 exhibits obvious tendency to bind strongly 
with certain wild-type and/or mutant members of the CDK 
and PDGFR subfamilies. Without being bound by any theory, 
the binding of compound 4 could be attributed to sterics, as 4 
is smaller in size than both 15 and 16 and that the targeted 65 
binding site of these subfamilies, CDK and PDGFR, is unable 
to accommodate these larger derivatives (15 and 16). Addi 
ABL1 (F317I) is moderately recognized by 4 (B-POC-30) 
60 and 16 (B-POC-20) whereas ABL1 (F317L) is more strongly 
recognized by 15 (B-POC-6.8). Since phosphorylated 
kinases are presumed to exist preferentially in the active state, 
the data Suggest that the test compounds interact with active 
kinases and inhibit their phosphotransferase function. 
Accordingly, a biochemical functional screening of the test 
compounds was pursued. Compound 4 is able to target 
PDGFR wild-type and mutants without affecting ABL1 or 
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ABL2 kinases (only phosphorylated ABL1 (F317I) mutant 
was targeted by 4). It is common for inhibitors binding to the 
ABL subfamily to also target the PDGFR subfamily and vice 
versa (See e.g., imatinib. Cohen, M. H. et al. Clinical Cancer 
Research 2002, 8,935-942; Dagher, R. et al. Clinical Cancer 
Research 2002, 8, 3034-3038). Compound 4 represents a 
structure that can discriminate between PDFGR and ABL 
subfamilies. Only interactions with B-POCs35 were consid 
ered significant and thus used for calculating the selectivity 
scores of the test compounds (Table 1, FIG. 2). The test 
compounds, as prototype kinase binders, have excellent over 
all selectivity towards certain kinase subfamilies. Based on 
the results of this primary single-dose screen, the concentra 
tion-dependent potential of compound 4 to bind to FLT3, 
KIT, KIT(D816H), or KIT(D816V) was investigated. The Kd 
(dissociation constant) of the four interactions was deter 
mined (Table 1). Dose responsecurves of compound 4 against 
FLT3, KIT, KIT(D816H), or KIT(D816V) are shown in FIG. 
3. 
In order to evaluate whether the molecules could inhibit the 
phosphotransferase kinase function a radiometric based assay 
was used to measure the ability of 1 uM of compounds 4, 15, 
or 16 to interfere with the function of a set of 55 protein 
kinases; 39 wild-type and 16 mutants (Table 5) (Davies, S. P. 
et al. Biochemical Journal 2000, 351, 95-105; Copeland, R. 
A. Analytical Biochemistry 2003, 320, 1-12). This set of 
tested kinases was chosen based on the results of the binding 
assay described above. Again the ability of 1 uM of a given 
test compound to inhibit the phosphotransferase function of a 
given kinase is expressed by functional percentage of control 
(F-POC) value which is also inversely proportional to the 
potency of the test compound, at that specific concentration, 
for a given kinase. The most promising interactions, at a 
single dose, were further investigated to determine the IC50 
values. The IC50 of compound 4 was determined against KIT, 
KIT(D816H), KIT(D816V), KIT(V560G), FLT3, PDGFRA 
(V561D), and PDGFRA(D842V) (Table 6). The results of 
kinase function inhibition assay are shown in Table 6, includ 
ing the F-POC of 1 uM of compounds 4, 15, and 16 against the 
most sensitive kinases tested within this experiment. Kinases 
are ranked according to their sensitivity towards binding by 
each compound separately from the most (lower F-POC) to 
the least (higher F-POC) sensitive. Kinases within the same 
subfamily are highlighted. The IC50 values of compound 4 
against a set of PDGFR subfamily selected kinases and 
mutants are in parentheses and expressed in M. Both the 
F-POC and ICs values are the average of duplicate measure 
ments. Dose-response curves were used to determine the 
IC50 values (FIG. 4). 
The three test compounds, weakly inhibit the same mem 
ber of CK1 subfamily, CSNK1D. Compound 4 demonstrates 
the ability to inhibit the function of some PDGFR subfamily 
members; both wild-type and mutants, without affecting ABL 
subfamily members. On the other hand, 15 and 16 show weak 




Wild-type (39) Abl, CDK2/cyclinA, CDK2, cyclinE, CDK6/cyclinD3, 
CK1, CK18, CK2, CK2C2, cKit, c-RAF, c-SRC, DDR2, 
EGFR, FGFR1, Flt3, IKKC., IKKB, JAK2, JAK3, 
JNK1C1, JNK2O2, JNK3, MAPK1, MAPK2, MEK1, 
Met, mTOR, p70S6K, PAK5, PDGFRC, PDGFRB, 
PDK1, PI3K/p85c., PI3K/p65C., PKBC, PKBB, 


















Kinase 4 Kinase 15 Kinase 16 
PDGFRA(V561D) 20 (0.295) ABL 80 MAPK1 73 
PDGFRA(D842V) 25 (0.316) FLT3 80 74 
KIT(D816H) 30 (0.316) PKBB 82 PKBB 83 
KIT(V560G) 36 (0.699) 87 KIT(V560G) 86 
FLT3 74 (6.692) AB. 87 
MET 75 Subfamily 
KITCD816V) 83 (2.823) PKB 





Both kinase profiling experiments, binding and functional, 
revealed that compound 4 shows more potential to either bind 
to or inhibit the function of Some of the KIT and PDGFRA 
mutants compared to their wild-type isoforms. The B-POC of 
10 uM and F-POC of 1 M of compound 4 measured in the 
binding and function inhibition experiments, respectively, are 
shown in Table 7. The location of each mutation is included 
(Gajiwaia, K. S. et al. Proceedings of the National Academy 
of Sciences of the United States of America 2009, 106, 1542– 
1547: Heinrich, M. C. et al. Science 2003, 299,708–710.). It 
has been reported that different gain-of-function mutations of 
the KIT kinase lead to constitutive catalytic activity indepen 
dent of activation by extracellular stem cell factor. The occur 
rence of these mutations was detected in cases where mar 
keted KIT inhibitors (imatinib, dasatinib and Sunitinib) face 
resistance by the target cancer cells and become inefficacious 
in the treatment of chronic myeloid leukemia (CML) and/or 
gastrointestinal stromal tumors (GIST) (Gajiwaia, K. S. et al. 
Proceedings of the National Academy of Sciences of the 
United States of America 2009, 106, 1542–1547: Masson, K.: 
Ronnstrand, L. Cellular Signalling 2009, 21, 1717-1726; 
Bougherara, H. et al. Molecular Cancer Research 2009, 7. 
1525-1533). Compound 4 shows higher activity against the 
KIT A-loop mutants; D816H and D816V compared to its 
activity against wild-type KIT which is supported by both the 
Kd values in the binding screen and the IC50 values in the 
functional assay. As common with many other kinase inhibi 
tors, mutations in the gatekeeper of KIT could render the 
protein less liable to binding by 4; an observation reinforced 
by the increase in the B-POC value of the juxtamembrane 
mutant KIT(V559D) upon mutation of the gatekeeper in the 
double mutant KIT(V559D, T670I). Without being bound by 
any theory, this may suggest that the gatekeeper residue and 
probably the adjacent hinge region are critical in binding of 4 
to KIT. It is clear that 4 can bind the KIT(D816V) (Kd=0.11 
uM) more than it binds KIT(D816H) (Kd=1.3 uM), whereas 
it inhibits the function of KIT(D816H) (IC50=0.316 uM) 
more than it inhibits KIT(D816V) (IC50=2.82 uM). Such 
opposite effects, on two different mutations at the same loca 
tion, may originate from the difference in the preferred con 
formational ensembles. Also, this highlights the potential 
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effect of a single amino acid mutation upon the probability 
distribution of the protein's conformations to be selected for 
binding by a given small molecule like 4. The ability of 
compound 4 to efficiently bind to certain KIT mutants, that 
are resistant to other kinase inhibitors, more than it binds to 
the wild-type suggest that 4 can be selective towards cancer 
phenotypes harboring and depending on Such mutant KIT 
forms versus normal cells depending mainly on wild-type 
KIT to function. Compound 4 also exhibits a similar fashion 
of selectivity towards certain PDGFRA mutants (V561D in 
the juxtamembrane or D842V in the A-loop) as illustrated by 
the F-POC and IC50 determination. Such PDGFRA mutants 
exhibit differential resistance towards certain kinase inhibi 
tors like imatinib and nilotinib and become common in cer 
tain forms of resistant cancer phenotypes (Heinrich, M. C. et 
al. Science 2003, 299, 708–710; Liegl-Atzwanger, B. et al. 
Virchows Archiv 2010, 456, 111-127; Pasini, B. et al. Journal 
of Clinical Endocrinology and Metabolism 2007, 92, 3728 




Kinase Location B-POC K (IM) F-POC (M) 
KIT(D816V) A-loop O.S O.11 83 2.82 
KIT(D816H) A-loop 30 1.3 30 O.316 
KIT(A829P) A-loop 84 ND ND ND 
KIT(V559D) JM 4.3 ND ND ND 
KIT(L576P) JM 9.8 ND ND ND 
KIT(V559D, T67OI) JM and GK 66 ND ND ND 
KIT(V560G) JM ND ND 36 O.699 
KIT Wild-type 9.1 2.5 94 -10.O 
PDGFRA(V561D) JM ND ND 2O O.295 
PDGFRA(D842V) A-loop ND ND 25 O.316 
PDGFRA Wild-type 21 ND 116 ND 
JM = juxtamembrane domain; 
GK = gatekeeper residue; 
ND = not determined. 
Compound 15 demonstrates a similar trend of selectivity 
towards the mutant BRAF(V600E) versus the wild-type 
BRAF (Table 1). BRAF(V600E) mutant is commonly found 
in several kinds of cancer especially melanoma and GIST. 
This mutation has attracted the attention of research groups to 
develop specific inhibitors against it (Liegl-Atzwanger, B. et 
al. Virchows Archiv 2010, 456, 111-127; Suijkerbuijk, B. M. 
J. M. et al. Journal of Medicinal Chemistry 2010, 53, 2741 
2756). ABL1 mutants have been generally shown to affect the 
sensitivity towards ABL kinase inhibitors. Point mutations in 
codon 317 of ABL1 have been found to specifically impart 
resistance towards dasatinib. 58-60 Compound 4 and 16 have 
moderate affinity to bind to the phosphorylated form of ABL1 
(F317I) while 15 has stronger binding affinity towards the 
phosphorylated form of ABL1(F317L). 
As revealed by Table 1 and Table 6, although compounds 4 
and 15 have certain common kinase targets, they do not share 
an overall similar selectivity profile in that 4 is more active 
towards the PDGFR subfamily. This is contrary to the corre 
lation of their cellular profile against the NCI-60 panel of 
cancer cells. One possible scenario is that 4 and 15 could 
equally inhibit other protein(s) that belong to a different pro 
tein family other than protein kinases. It also may be possible 
that 4 and 15 target the same signaling transduction pathway 
at different points. 
The observed binding affinity of 4 against the wild-type 
KIT and its D816V mutant, obtained from the binding data, to 
the respective binding affinity of 38 kinase inhibitors against 













tal conditions, is shown in Table 8 (Karaman, M. W. et al. 
Nature Biotechnology 2008, 26, 127-132). The K values of 
the reference kinase inhibitors were determined experimen 
tally against the two kinases similarly to that of 4 and were 
obtained from literature. AAG, as a measure of the differen 
tial binding potential against the mutant KIT(D816V) versus 
the wild-type KIT, was calculated according to the literature 
(Kolb, P. et al. Journal of Medicinal Chemistry 2008, 51, 
1179-1188: Abdul Hameed, M. D. M. et al. Journal of Physi 
cal Chemistry B 2006, 110,26365-26374). A negative AAG 
indicates preferential binding to the mutant whereas a posi 
tive AAG indicates increased resistance by the mutant 
against the specific inhibitor. 
The data in Table 8 show that the seven reference kinase 
inhibitors that have negative AAG are known to be type-I 
kinase inhibitors which bind to the same binding site occu 
pied by ATP (Fedorov, O. et al. Proceedings of the National 
Academy of Sciences of the United States of America 2007, 
104, 20523-20528; Rixe, O. et al. Cancer Chemotherapy and 
Pharmacology 2009, 64, 1139-1148: Weisberg, E. et al. 
Blood 2008, 112,5161-5170; Baumli, S. etal. EMBOJournal 
2008, 27, 1907-1918; Yun, C. H. et al. Cancer Cell 2007, 11, 
217-227: Boggon, T. J. et al. Blood 2005, 106, 996-1002: 
Stamos, J. et al. Journal of Biological Chemistry 2002, 277, 
46265-46272). The above observation matches with several 
published computational as well as experimental reports 
demonstrating that an aspartic acid to Valine mutation in the 
position 816 of KIT destabilizes the inactive (DFG-out) con 
formations of KIT. The same mutation would consequently 
decrease the binding to type-II kinase inhibitors which 
mainly bind preferentially to the inactive (DFG-out) confor 
mational ensemble of KIT. In addition, the experimental ten 
dency of 4 to bind better to the V816KIT compared to the 
D816KIT suggests that 4 may be a type-I kinase inhibitor that 
targets the ATP binding site in contrast to type-II inhibitors 
which exploit the adjacent allosteric binding site. 
TABLE 8 
K (nM 
Kinase inhibitor KIT KIT(D816V) AAG 
Staurosporine 19 O.64 -2.01 
PKC-412 220 7.7 -1.98 
4 2SOO 110 -1847 
LY-333531 >1OOOO 920 <-1.4 
Erlotinib >1OOOO 1600 <-1.08 
Gefitinib >1OOOO 43OO <-049 
Flavopiridol >1OOOO 4600 <-0.45 
CI-1033 7800 3900 -0.41 
ZD-6474 260 290 O.O6 
VX-680 240 290 O.11 
JN-7706621 1800 2SOO O.19 
Dasatinib O.62 2.6 O.85 
Sorafenib 31 310 1.36 
MLN-518 2.7 29 140 
CHIR-265 2OO 62OO 2.03 
ABT-869 2 81 2.19 
Imatinib 14 82O 2.41 
BIRB-796 170 >1OOOO >241 
AST-487 5.4 360 2.48 
AMG-7O6 3.7 410 2.78 
GW-78.6034 2.8 500 3.07 
CHIR-258 7.5 14OO 3.09 
AZD-1152HQPA 17 4600 3.31 
SU-14813 O.68 340 3.68 
Sunitinib 0.37 380 4.10 
PTK-787 S.1 >1OOOO >4.48 
BMS-387O32 >1OOOO >1OOOO 
CP-690550 >1OOOO >1OOOO 
CP-724714 >1OOOO >1OOOO 
EKB-569 >1OOOO >1OOOO 




Kinase inhibitor KIT KIT(D816V) AAG 
GW-2580 >1OOOO >1OOOO 
Lapatinib >1OOOO >1OOOO 
MLN-8054 >1OOOO >1OOOO 
PI-103 >1OOOO >1OOOO 
Roscovitine >1OOOO >1OOOO 
SB-2021.90 >1OOOO >1OOOO 
SB-2O358O >1OOOO >1OOOO 
SB-431542 >1OOOO >1OOOO 
VX-745 >1OOOO >1OOOO 
AAG (Kcal mol) = Rx TX ln K(mutant), K(wild-type) where R = 0.001985 Kcal 
mol K and T = 298°K. 
Treatment of Breast Tumor Cell Line MDA-MB-468 with 
Compound 15 
Treatment of the breast tumor cell line MDA-MB-468 with 
compound 15 caused the cells to arrest at the G2/M phase of 
the cell cycle within 24 hours (see FIG. 7). At higher doses a 
significant fraction of the tumor cells undergo apoptosis 
within 24 hours, as assessed by Annexin Vassay (see FIG. 8). 
Although the compounds, compositions, and methods 
described herein have been described in connection with 
Some variations and/or embodiments, it is not intended to be 
limited to the specific form set forth herein. Rather, the scope 
of the methods described herein is limited only by the claims. 
Additionally, although a feature may appear to be described 
in connection with particular variations, one skilled in the art 
would recognize that various features of the described varia 
tions and/or embodiments may be combined in accordance 
with the methods described herein. 
Although individual features of the compounds, composi 
tions, and methods described herein may be included in dif 
ferent claims, these may be advantageously combined, and 
the inclusion in different claims does not imply that a com 
bination of features is not feasible and/or advantageous. Also, 
the inclusion of a feature in one category of claims does not 
imply a limitation to this category, but rather the feature may 
be equally applicable to other claim categories, as appropri 
ate. Where a compound, composition, or method comprises 
one or more specified items or steps, others can also be 
included. The invention also contemplates, however, that the 
described compounds, compositions, or methods may be 
used without other items or steps and thus it includes the 
recited composition or process consisting of or consisting 
essentially of the recited items, materials or steps, as those 
terms are commonly understood in patent law. 
Terms and phrases used in this document, and variations 
and/or embodiments thereof, unless otherwise expressly 
stated, should be construed as open ended as opposed to 
limiting. As examples of the foregoing: the term “including 
should be read to mean “including, without limitation' or the 
like; the terms “example' or “some variations” are used to 
provide exemplary instances of the item in discussion, not an 
exhaustive or limiting list thereof, and adjectives such as 
“conventional,” “traditional,” “normal,” “standard,” “known 
and terms of similar meaning should not be construed as 
limiting the item described to a given time period or to an item 
available as of a given time, but instead should be read to 
encompass conventional, traditional, normal, or standard 
technologies that may be available or known now or at any 
time in the future. Likewise, a group of items linked with the 
conjunction “and” should not be read as requiring that each 
and every one of those items be present in the grouping, but 
rather should be read as “and/or unless expressly stated 













junction 'or' should not be read as requiring mutual exclu 
sivity among that group, but rather should also be read as 
“and/or unless expressly stated otherwise. Furthermore, 
although items, elements or components of methods and 
compositions described herein may be described or claimed 
in the singular, the plural is contemplated to be within the 
Scope thereof unless limitation to the singular is explicitly 
stated. The presence of broadening words and phrases such as 
“one or more.” “at least,” “but not limited to,” “in some 
embodiments, or other like phrases in some instances shall 
not be read to mean that the narrower case is intended or 
required in instances where such broadening phrases may be 
absent. 
ENUMERATED EMBODIMENTS 
The following enumerated embodiments are representa 
tive of some aspects of the invention. 
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R9 R. R. N 
R R 7 -N "k RN1S2 O R 14 N 
R \ X-N N-Q 
N (R12) 
R5 R8 m pi 
R R. R. R.13 
15 R 16 
R 
(III) 
R9 R2 R3 
Sk R4 =N R 14 N 
R10 \ X-N N-Q /= 
N N Y K I6 R11 R. R8 R16 V / 
N. 
R15 R17 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 
ring atoms, or may be a 5-6 membered ring that is fused 
with or bonded to one or more additional aryl, hetero 
cyclic, or heteroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
Selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R, R', R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally substituted 
alkyl, or optionally substituted aryl, halo, OR, NR, SR, 
S(O)R, SOR, SONR, NRSOR, NRCONR, 
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NRCOOR, NRCOR, CN, COOR, CONR, OOCR, 
COR, CH(OH)R, and NO, wherein each R is indepen 
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk 
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het 
eroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, 
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and 
wherein each R is optionally substituted, with the pro 
viso that R' for formula (I) must not be hydrogen; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
2. The compound of embodiment 1, which is a compound 
of formula (I) or a pharmaceutically acceptable salt thereof. 
3. The compound of embodiment 1, which is a compound 
of formula (II) or a pharmaceutically acceptable salt thereof. 
4. The compound of embodiment 1, which is a compound 
of formula (III) or a pharmaceutically acceptable salt thereof. 
5. The compound of any of embodiments 3-4, wherein Q is 
C O. 
6. The compound of any of embodiments 1-5, wherein each 
R", R. R. R. R. R. R', and Rishydrogen. 
7. The compound of any of embodiments 1-6, wherein each 
RandR'' is independently selected from hydrogen, option 
ally substituted alkyl, optionally substituted aryl, halo, OR, 
NRSR, CN, COOR, CONR, COR, CH(OH)R, and NO. 
8. The compound of any of embodiments 1-7, wherein each 
R" is independently selected from optionally substituted 
alkyl, optionally substituted aryl, halo, OR, NR, SR, CN, 
COOR, CONR, COR, CH(OH)R, and NO. 
9. The compound of any of embodiments 1-8, wherein each 
R" is independently selected from optionally substituted 
alkyl or optionally substituted aryl. 
10. The compound of any of embodiments 1-9, wherein 
each R" is -(CH2). Ar, wherein p is 1-2 and Aris option 
ally substituted phenyl. 
11. The compound of any of embodiments 1-10, wherein 
each R and R'' is hydrogen and each R' is optionally sub 
stituted alkyl. 
12. The compound of any of embodiments 1-11, wherein 
each R" is independently selected from methyl, ethyl, pro 
pyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 
neopentyl, and benzyl. 
13. The compound of any of embodiments 1-12, wherein 
each R' is independently selected from optionally substi 
tuted ethyl or benzyl. 
14. The compound of any of embodiments 1-13, wherein 
each R" is independently selected from optionally substi 
tuted alkyl, optionally substituted aryl, halo, OR, NR, SR, 
CN, COOR, CONR, COR, CH(OH)R, and NO. 
15. The compound of any of embodiments 1-14, wherein 
each R'' is hydrogen. 
16. The compound of any of embodiments 1-15, wherein 
W in any compound having formula (I), (II), or (III) is: 














17. The compound of embodiment 16, wherein W is 
selected from the group consisting of: 
(R2) 
wherein each R' is independently selected from the group 
consisting of hydrogen, optionally Substituted alkyl, 
optionally substituted aryl, halo, OR, NR, SR, CN, 
COOR, CONR, COR, CH(OH)R, and NO. 
18. The compound of embodiment 17, wherein W is 
selected from the group consisting of: 
20. The compound of any of embodiments 1-15, wherein 
W in any compound having formula (I), (II), or (III) is: 
wherein X and Y are N or CR': 
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Z is selected from the group consisting of NR", O, and S; 24. The compound of embodiment 23, wherein W is 
and selected from the group consisting of: 
R’ is hydrogen or R''. 
21. The compound of embodiment 20, wherein W is s 
selected from the group consisting of: N--- N--- 
# W 
s 
- N - - - - - - - - N 
M Vvvvr M M and 
N--- N---, 10 
... ', HN O 
- N ----&---- N af2 Né R12 
}= ) \ R12 
N O Nn-NH N 
15 N- - - 
R 
R12 R' ------- - N 
- N A. 2O N. rviv rivn - N 
w A. and Vvvv, wr: 
1-\ = R12 
N-S N NH 
Y N / 2 2s wherein each R' is independently selected from the group 
R consisting of hydrogen, optionally Substituted alkyl, and 
optionally substituted aryl. 
wherein each R'' is independently selected from the group 25. The compound of embodiment 24, wherein W is 
consisting of hydrogen, optionally Substituted alkyl, and selected from the group consisting of: 
optionally substituted aryl. 30 
22. The compound of embodiment 21, wherein W is 
selected from the group consisting of: N N 
3s ----s--- - N ----&--- - N 
N---, N--- o o 
- N -------- N HNS a OS a 
rArr rvin WVVV wrviv and N 
w F w A. N--- 
}= }= 40 A 
- N 
N-NH N- myV M 
- - - N NR, 'Ne 
- N 45 
1-\ 26. The compound of embodiment 1, wherein the com 
N- S pound is: 
50 
N N 
23. The compound of any of embodiments 1-15, wherein / V / \ 
R10 N N N: N / 
N 
W in any compound having formula (I), (II), or (III) is: W 
- N 
Vvvv, wr: (R2) 
XN 27. 60 O Y wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted 
aryl; 
2O 
with selected from the group consisting of NR', and wherein each R" is independently selected from the 
s s 12 65 group consisting of hydrogen, optionally Substituted 
Y and Z are N or CR'?; and alkyl, optionally substituted aryl, halo, OR, NR, SR, 
R’ is hydrogen or R''. CN, COOR, CONR, COR, CH(OH)R, and NO. 
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27. The compound of embodiment 26, wherein the com 
pound is: 
=N / \ 
\ -( ) 
10 
28. The compound of embodiment 1, wherein the com 
pound is: 
=N O N 
O A 
R -(- N 3-y 
NH - SS (R): 
wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted 
aryl; 
and wherein each R'' is independently selected from the 
group consisting of hydrogen, optionally substituted 
alkyl, optionally substituted aryl, halo, OR, NR, SR, 
CN, COOR, CONR, COR, CH(OH)R, and NO. 






=N /- O / N 40 
\ X-N N N N \ / W. 
NH 
45 




N / \ O 
R-(-O HN N-y : y y \ y 
\/ 
(R2) 
wherein R' is selected from the group consisting of 60 
optionally substituted alkyl and optionally substituted 
aryl; 
and wherein each R" is independently selected from the 
group consisting of hydrogen, optionally substituted 65 
alkyl, optionally substituted aryl, halo, OR, NR, SR, 
CN, COOR, CONR, COR, CH(OH)R, and NO. 
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31. The compound of embodiment 30, wherein the com 
pound is: 
N / \ O 
N - N 
32. The compound of embodiment 1, wherein the com 
pound is: 
N O 
R- X-N N 
N \ / / v y 
NH PS(R2) 
wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted 
aryl; 
and wherein each R" is independently selected from the 
group consisting of hydrogen, optionally Substituted 
alkyl, optionally substituted aryl, halo, OR, NR, SR, 
CN, COOR, CONR, COR, CH(OH)R, and NO. 
33. The compound of embodiment 32, wherein the com 
pound is: 
N / \ O 
/-(-O N \ / / R. sy 
NH 
34. A pharmaceutical composition comprising a com 
pound according to any of embodiments 1-33 and at least one 
pharmaceutically acceptable excipient. 
35. The use of a compound according to any of embodi 
ments 1-33 to manufacture a medicament. 
36. The method of embodiment 35, wherein the medica 
ment is a medicament for the treatment of a proliferative 
disorder. 
37. A method to identify a molecule that modulates protein 
kinase activity, said method comprising screening a com 
pound according to any of embodiments 1-33, to identify a 
compound having an effect on the activity of a protein kinase. 
38. A method to treat a proliferative disorder, said method 
comprising administering to a Subject in need of Such treat 
ment, an effective amount of a compound of formula (I), (II), 
or (III): 
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R9 R. R. N 
R R 7 
N R 21 
R 14 N 
R10 \ X-N N-Q 
N Y K (R12) 
R11 R5 R6 R7 R8 )m pi 
R13 
15 R 16 
R 
(III) 
R9 R2 R3 
R 
EN R 14 N 
R10 \ y-N N-Q /= 
N N s Sos R16W / 
R11 R R7 R 2 R R13 (R'); 
N 
R 15 YR 7 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 
ring atoms, or may be a 5-6 membered ring that is fused 
with or bonded to one or more additional aryl, hetero 
cyclic, or heteroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
Selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R. R. R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally substituted 
alkyl, or optionally substituted aryl, halo, OR, NR, SR, 
S(O)R, SOR, SONR, NRSOR, NRCONR, 
NRCOOR, NRCOR, CN, COOR, CONR, OOCR, 
COR, CH(OH)R, and NO, wherein each R is indepen 
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk 
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het 
eroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, 
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and 
wherein each R is optionally substituted; and 
each R'7 is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
39. The method of embodiment 38, wherein the prolifera 
tive disorder is a tumor or a cancer in a human or animal 
Subject. 
40. The method of embodiment 39, wherein the cancer is 
selected from the group consisting of leukemia, non-Small 
cell lung cancer, colon cancer, central nervous system (CNS) 
cancer, melanoma, ovarian cancer, renal cancer, prostate can 













41. A method to reduce cell proliferation, said method 
comprising administering to a cell in an in vitro or in vivo 
environment, an effective amount of a compound of formula 










R9 R. R. N 
R R 7 
EN RN 21 
R 14 N 
R10 \ X-N N-Q 
N (R12) 
R5 R8 m pi 
R R. R. R.13 
15 R 16 
R 
(III) 
R9 R2 R3 
R 
=N R 14 N 
R10 \ X-N N-Q /= 
N N s S. R16W / 
R11 R R6 R7 R 2 R13 (R'); 
N 
R15 YR 7 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 
ring atoms, or may be a 5-6 membered ring that is fused 
with or bonded to one or more additional aryl, hetero 
cyclic, or heteroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
Selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R, R', R'', R12, R', R', R', and R' is indepen 
dently selected from hydrogen, optionally substituted 
alkyl, or optionally substituted aryl, halo, OR, NR, SR, 
S(O)R, SOR, SONR, NRSOR, NRCONR, 
NRCOOR, NRCOR, CN, COOR, CONR, OOCR, 
COR, CH(OH)R, and NO, wherein each R is indepen 
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk 
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het 
eroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, 
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and 
wherein each R is optionally substituted; and 
each R'7 is independently selected from hydrogen or 
optionally substituted alkyl; 
or a pharmaceutically acceptable salt thereof. 
42. The method of embodiment 41, wherein the cell is a 
cancer cell, and wherein the cancer is selected from the group 
consisting of leukemia, non-Small cell lung cancer, colon 
cancer, central nervous system (CNS) cancer, melanoma, 
ovarian cancer, renal cancer, prostate cancer, and breast can 
C. 
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43. A method to induce cell death, said method comprising 
administering to a cell in an in vitro or in vivo environment, an 
effective amount of a compound of formula (I), (II), or (III): 
(I) 




R9 R. R. N 
R R 7 
N RN 21 
R 14 N 
R10 \ X-N N-Q 
N Y K (R12) 
R11 R5 R6 R7 R8 )m pi 
R13 
15 R 16 
R 
(III) 
R9 R2 R3 
wherein m is 0 or 1; 
each n is independently 0-6: 
each W represents an optionally substituted aryl or het 
eroaryl ring, which may be a monocyclic group with 5-6 
ring atoms, or may be a 5-6 membered ring that is fused 
with or bonded to one or more additional aryl, hetero 
cyclic, or heteroaryl rings; 
each Q is CH, SO, or C=O; 
each R', R. R. R. R. R. R7, and R is independently 
Selected from hydrogen, optionally Substituted alkyl, or 
optionally substituted aryl; 
each R. R. R'', R. R. R. R', and R' is indepen 
dently selected from hydrogen, optionally substituted 
alkyl, or optionally substituted aryl, halo, OR, NR, SR, 
S(O)R, SOR, SONR, NRSOR, NRCONR, 
NRCOOR, NRCOR, CN, COOR, CONR, OOCR, 
COR, CH(OH)R, and NO, wherein each R is indepen 
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk 
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het 
eroalkynyl, C3-C8 heterocyclyl, C4-C10 
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, 
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and 
wherein each R is optionally substituted; and 
each R'' is independently selected from hydrogen or 
optionally substituted alkyl; 













44. The compound of embodiment 1, wherein one or more 
R. R', R' or R'' are independently halo. 
45. The compound of embodiment 44, wherein each R" is 
bromo. 
46. The compound of embodiment 44, wherein each R' is 
fluoro. 
47. The compound of any of embodiments 44-46, wherein 
the compound is: 
n-()-O N-y \ / 
48. The compound of any of embodiments 44-46, wherein 
the compound is: 
N / \ O 




1. A compound of formula (I): 
(I) 
"Sk" - N N 
R10 X-N N W \ 
N / Y-K N R5 R8 o 
R11 R6 R7 
(R12) 
wherein 
n is independently 0-6: 
W represents an optionally substituted aryl or heteroaryl 
ring, which may be a monocyclic group with 5-6 ring 
atoms, or may be a 5-6 membered ring that is fused with 
or bonded to one or more additional aryl, heterocyclic, or 
heteroaryl rings; 
each R', R. R. R. R. R. R', and R is independently 
Selected from hydrogen, optionally Substituted alkyl, or 
optionally Substituted aryl; and 
each R. R', R'', and R' is independently selected from 
hydrogen, optionally Substituted alkyl, or optionally 
substituted aryl, halo, OR, NR, SR, S(O)R, SOR, 
SONR, NRSOR, NRCONR, NRCOOR, NRCOR, 
CN, COOR, CONR, OOCR, COR, CH(OH)R, and 
NO, wherein each R is independently H, C1-C8 alkyl, 
C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalk 
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enyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C3-C8 het 
erocyclyl, C4-C10 heterocyclyclalkyl, C6-C10 aryl, 
C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 het 
eroarylalkyl, and wherein each R is optionally substi 
tuted, with the proviso that R' must not be hydrogen; 
or a pharmaceutically acceptable salt thereof. 
2. The compound of claim 1, wherein R' is independently 
selected from optionally substituted alkyl, optionally substi 
tuted aryl, halo, OR, NR, SR, CN, COOR, CONR, COR, 
CH(OH)R, and NO. 
3. The compound of claim 1, wherein each R" is indepen 
dently selected from optionally substituted alkyl, optionally 
substituted aryl, halo, OR, NR SR, CN, COOR, CONR, 
COR, CH(OH)R, and NO. 
4. The compound of claim 1, wherein the compound is: 
=N / V V 
(R2) 
wherein R' is selected from the group consisting of 
optionally substituted alkyl and optionally substituted 
aryl; 
and wherein each R" is independently selected from the 
group consisting of hydrogen, optionally substituted 
alkyl, optionally substituted aryl, halo, OR, NR, SR, 





5. The compound of claim 4, wherein the compound is: 
6. The compound of claim 1, wherein the compound is: 
Br / V / \, 
-(-)- \ / 
N-y 
\ / 
7. A pharmaceutical composition comprising a compound 
of claim 1 and at least one pharmaceutically acceptable 
excipient. 
8. A method to inhibit a tyrosine kinase of a platelet derived 
growth factor receptor (PDGFR) comprising administering a 
pharmaceutical composition comprising a compound or salt 
of claim 1. 
9. The method of claim 8, wherein the tyrosine kinase of 
the platelet derived growth factor receptor (PDGFR) is 
selected from the group consisting of PDGFRC, PDGFRB, 
KIT, Flt3, and CSF1R. 
k k k k k 
